

# Author Index for 1996

- Abbruzzese, M., 58:37  
 Achiron, A., 58:177  
 Ackenheil, M., 59:7  
 Adams, P.B., 57:169  
 Addis, I.B., 56:111  
 Adès, J., 59:255  
 Adinoff, B., 59:127  
 Agbayewa, O., 60:33  
 Agras, W.S., 58:13  
 Akerman, D., 56:11  
 Akers, L., 60:41  
 Albers, L.J., 57:275, 59:189, 60:177  
 Alpert, R., 60:167  
 Ancoli-Israel, S., 57:7  
 Anderson, B., 56:17  
 Anderson, J., 56:229, 56:237, 58:69  
 Apter, S., 57:109  
 Arbi, P.A., 59:171  
 Armitage, R., 56:245  
 Arnov, B., 58:13  
 Aronson, A., 59:127  
 Asmundson, G.J.G., 59:183  
 Asnis, G.M., 60:191  
 Avanzini, P., 58:153  
  
 Bagby, R.M., 58:139  
 Balon, R., 56:289, 60:77  
 Bar-Ziv, J., 58:259  
 Barak, Y., 58:177  
 Bardgett, M.E., 58:117  
 Barker, B.A., 57:83  
 Barry, R.J., 56:229, 56:237, 58:69  
 Bartlett, E.J., 60:91  
 Barzaga, G., 57:49  
 Bastürk, M., 59:165  
 Batra, A., 59:251  
 Baumgartner, A., 56:81  
 Beam-Goulet, J., 56:45  
 Bean, G., 59:109  
 Beckmann, P., 56:257  
 Beckmann, H., 59:17  
 Beiser, M., 56:145, 59:109  
 Bell, M., 56:45  
 Bellack, A.S., 56:121, 57:141  
 Bellino, S., 57:49  
  
 Bellodi, L., 57:267, 58:265  
 Benson, K.L., 60:125  
 Berchou, R., 56:289, 60:77  
 Bergman, A., 57:131  
 Berrios, G.E., 56:183  
 Bertollo, D.N., 60:113  
 Beaumont, P.J.V., 56:229, 56:237  
 Bielski, R.J., 56:221  
 Bierer, L.M., 58:181  
 Bierhals, A.J., 59:65  
 Bird, H., 57:169  
 Blanchard, J.J., 57:141  
 Bleich, A., 58:259  
 Blouin, J.H., 60:1  
 Blouin, A.G., 60:1  
 Bodeau-Péan, S., 59:1  
 Bogetto, F., 57:49  
 Bonato, R., 56:245  
 Bondoux, D., 58:191  
 Bondy, B., 59:7  
 Booker, J.M., 57:251  
 Bouhuys, N., 57:223  
 Bourdel, M.-C., 57:41  
 Boutros, N.N., 57:57, 57:83  
 Bouvard, M.P., 58:191, 59:255, 60:101  
 Boyer, P., 60:57  
 Brambilla, F., 58:153, 59:43, 59:51  
 Bräunig, P., 57:21  
 Breier, A., 56:33  
 Brekke, J.S., 57:241  
 Bremner, J.D., 59:97  
 Breslau, N., 58:1  
 Brodie, J.D., 60:91  
 Bröker, M., 58:77  
 Brown, A.S., 57:231  
 Brown, R.J., 56:53  
 Bruce, B., 58:13  
 Brunetta, M., 59:43, 59:51  
 Brunner, J., 58:165  
 Bryant, N.L., 56:33  
 Buchanan, R.W., 56:33, 59:221  
 Buitelaar, J.K., 58:203  
 Burgess, A., 56:71  
 Burns, E.M., 57:57  
 Buss, T.J.R., 59:197  
 Byrne, M., 59:119  
  
 Caccavari, R., 58:153  
 Calabrese, J., 58:217  
 Caldirola, D., 57:267  
 Caligiuri, M.P., 57:279  
 Calloway, S.P., 56:183  
 Campeas, R.B., 58:127  
 Campion, D., 59:1, 59:25  
 Cancro, R., 60:91  
 Cannon, M., 59:119  
 Capelli, S., 59:97  
 Carbone, K.M., 56:33  
 Carey, G., 56:213  
 Caro, F., 58:45  
 Carpenter, W.T., Jr., 56:33  
 Carter, C.S., 56:59  
 Carter, J., 60:1  
 Cascella, N.G., 58:53  
 Cassidy, B., 59:119  
 Castro, J.O., 60:23  
 Censits, D.M., 60:135  
 Cestaro, V., 60:167  
 Chaderjian, M., 56:59  
 Chang, W.-H., 57:101  
 Chang, L.-S., 57:65  
 Charney, D.S., 59:97  
 Chartier, M.J., 59:183  
 Chen, C.-C., 57:197  
 Chen, E.Y.H., 56:183  
 Chen, Y.-W., 59:57  
 Chhay, H., 60:177  
 Chien, C.-P., 57:101  
 Chung, M.-C., 57:101  
 Cinotti, L., 60:101  
 Clark, W.C., 56:173  
 Claus, D., 56:279  
 Cloitre, M., 59:245  
 Cohen, L.J., 58:161  
 Convit, A., 59:161  
 Cook, E.H., Jr., 57:13  
 Cooke, R.G., 58:139  
 Cooper, T.B., 59:161  
 Coplan, J.D., 58:127  
 Cordás, T.A., 56:11  
 Cornblatt, B., 57:131  
 Cornwell, A., 58:247  
 Corrigan, P.W., 56:111

- Cottraux, J., 60:101  
 Cowen, M.A., 60:113  
 Crocq, M.-A., 60:23  
 Csernansky, J.G., 58:117  
 Cuesta, M.J., 58:45, 58:227  
  
 d'Amato, T., 59:1, 60:205  
 Daléry, J., 60:205  
 Daveloose, D., 59:255  
 Davidson, M., 57:109, 59:127, 60:87  
 Davies, S.O., 58:127  
 Davis, S., 56:163  
 Davis, K.L., 57:109, 58:181  
 Davis, L.L., 60:41  
 Daviss, S.R., 59:81  
 DeCaria, C., 58:161  
 DeCarli, C., 57:119  
 Deiber, M.-P., 60:101  
 de Jong, J., 58:83  
 Deka, R., 59:35  
 Delaney, R., 59:97  
 de Leon, J., 58:45  
 Delsignore, R., 58:153  
 DeMet, E.M., 57:197  
 Dening, T.R., 56:183  
 Desnyder, R., 58:217  
 deVegvar, M.L., 59:127  
 Dewart, D., 58:247  
 Dewey, S.L., 60:91  
 Dhalla, K.S., 59:183  
 Dietrich, M., 59:251  
 Dillon, D.J., 58:127  
 Dilsaver, S.C., 59:57  
 Dogan, P., 59:165  
 Dollfus, S., 59:1  
 Doman, J., 59:65  
 Draisci, A., 59:43  
 Dugas, M., 58:191, 59:255  
 Dunayevich, E., 57:209  
 DuPre, R., 60:49  
 Duval, F., 60:23  
 Dworkin, R.H., 56:173  
  
 Egan, M.F., 56:53  
 Eisdorfer, C., 59:145  
 El-Mallakh, R.S., 59:197  
 Ellison, T., 57:13  
 Ercegovac, D.V., 58:247  
 Erzegovesi, S., 58:265  
 Esel, E., 59:165  
  
 Faraone, S.V., 56:135  
 Fasiczka, A., 59:65  
 Fava, M., 56:205, 56:295  
 Fell, J., 56:257  
 Ferri, S., 58:37  
 Fertonani, G., 58:153  
  
 Fishman, B., 59:245  
 Fitch, T., 56:245  
 Fleming, K., 56:155  
 Flores, C.V., 56:101  
 Frank, E., 56:17, 59:65  
 Franzek, E., 59:17  
 Freedman, R., 56:271  
 Friedland, N., 58:259  
 Friedman, J.H., 57:231  
 Froment, J.-C., 60:101  
 Fyer, A.J., 58:127  
  
 Gabriele, A., 57:267  
 Galinowski, A., 57:41  
 Gallacher, F., 60:135  
 Galy, G., 60:JC  
 Garvey, M.J., 57:1, 60:185  
 Gattaz, W.F., 58:165  
 Geerts, E., 57:223  
 Gérard, D., 60:101  
 Gerra, G., 58:153  
 Gevirtz, R., 57:7  
 Giannelli, A., 56:295  
 Gillin, J.C., 58:23, 58:99  
 Glahn, D.C., 60:135  
 Glicksohn, J., 58:259  
 Gold, J.M., 56:155  
 Goldberg, T.E., 56:155  
 Goldfield, G., 60:1  
 Goldstein, C., 60:1  
 Goldstein, M.J., 57:155  
 Golshan, S., 58:99  
 Gonsalvez, C.J., 56:237, 58:69  
 Gönül, A.S., 59:165  
 Goossens, F., 58:217  
 Gordon, B., 57:75  
 Gordon, E., 56:229, 56:237, 58:69  
 Gorman, J.M., 57:231, 58:127  
 Gottesman, I.I., 56:213  
 Gräf, K.-J., 56:81  
 Griffith, J.M., 56:271  
 Gross, G., 57:21  
 Gruzelier, J., 56:71, 56:163  
 Guaraldi, G.P., 56:295  
 Guillaud-Bataille, J.-M., 60:205  
 Guo, S.L., 57:109  
 Gur, R.C., 60:135  
 Gur, R.E., 60:135  
 Gurklis, J.A., 60:11  
 Gurrera, R.J., 56:25  
 Gynther, L.M., 56:213  
  
 Halaris, A., 57:21  
 Hallmayer, J., 59:7  
 Harvey, P.D., 59:127, 60:49, 60:87  
 Hauger, R.L., 58:23, 59:183  
 Hedley, L.M., 56:1  
  
 Heinz, A., 56:81  
 Helmeste, D., 57:275, 59:189, 60:177  
 Hembree, W.C., 57:231  
 Herzog, D.B., 56:205  
 Heuser, I., 59:157  
 Hilwig, M., 56:299  
 Hodges, J.R., 56:183  
 Hoff, A.L., 60:167  
 Hoffart, A., 56:1  
 Hoffmann, R., 56:245  
 Hofman, A., 56:299  
 Holcomb, H.H., 57:75, 58:53  
 Hollander, E., 58:161  
 Holsboer, F., 59:157  
 Honig, A., 56:299  
 Horgan, R., 59:119  
 Horvath, T.B., 57:109  
 Horwitz, B., 57:119  
 Houck, P.R., 56:17  
 Hoven, C.W., 57:169  
 Huang, H.-F., 57:101  
 Huang, Y.-H., 57:65  
 Huber, G., 57:21  
 Huggins, T.S., 57:259  
 Husted, J.A., 56:145  
 Huttunen, M.O., 58:145  
 Hwang, M., 58:161  
 Hyde, T.M., 56:53  
 Hymas, N.F.S., 56:183  
  
 Iacono, W.G., 56:145, 59:109  
 Irving, G., 56:71  
 Islam, N., 58:161  
 Iversen, H., 60:1  
 Iwata, N., 58:237  
  
 Jackson, J.L., 58:117  
 Jackson, P., 58:247  
 Jacobsberg, L., 59:245  
 Jacobson, R., 58:181  
 Jann, M.W., 57:101  
 Jansen, J., 57:223  
 Jay, M., 59:1, 59:25, 60:205  
 Jenck, F., 57:181  
 Jerushalmy, Z., 57:193  
 Joffe, R.T., 58:139  
  
 Kallio, E., 58:145  
 Kaplan, Z., 60:199  
 Kärkkäinen, J., 58:145  
 Kaschka, W.P., 56:279  
 Kasper, S., 56:11  
 Katz, M., 57:275  
 Kaufmann, C.A., 57:231  
 Kawakami, N., 58:237  
 Keck, P.E., Jr., 57:209  
 Keefe, R.S.E., 59:127, 60:49

- Kellner, M., 59:157  
 Kelsoe, J.R., 58:99  
 Kenny, W.M., 58:99  
 Keshavan, M.S., 57:91, 59:203, 60:117  
 Kikinzon, L., 57:193  
 Kim, C., 59:221  
 Klein, D.F., 58:127  
 Klein, R., 59:251  
 Kleinman, J.E., 56:53  
 Klemfuss, H., 57:215  
 Kling, M.A., 57:259  
 Koran, L.M., 58:13  
 Köse, K., 59:165  
 Koziol, J.A., 59:239  
 Kraemer, H.C., 58:13  
 Krakowski, H., 59:161  
 Kramer, G.L., 59:127, 60:41  
 Kremen, W.S., 56:135  
 Krener, P., 56:59  
 Kripke, D.F., 57:215  
 Krishnan, R.R., 60:117  
 Kumar, M., 59:145  
 Kumar, A.M., 59:145  
 Kunz, M., 59:161  
 Kupfer, D.J., 56:17, 57:91  
 Kürten, I., 56:81  
  
 Labbé, C., 60:101  
 Lahti, A., 59:221  
 Lam, R.W., 60:33  
 Lampl, Y., 58:177  
 Larkin, C., 59:119  
 Laukes, C., 57:1  
 Launay, J.-M., 58:191  
 Laurent, C., 59:1  
 Lauriello, J., 58:99, 60:125  
 Lavenne, F., 60:101  
 Lawlor, B.A., 58:181  
 Le Bars, D., 60:101  
 Lebell, M.B., 57:155  
 Leboyer, M., 58:191  
 Lees-Roitman, S., 59:127, 60:49  
 Lefton, R.S., 56:101  
 Lejoyeux, M., 59:255  
 Lensing, P., 58:191  
 Leonard, H.L., 60:67  
 Leventhal, B.L., 57:13  
 Levine, A.S., 59:171  
 Levine, J., 60:199  
 Levitt, A.J., 58:139  
 Levy, A.V., 60:113  
 Lewis, D.A., 59:81  
 Li, R., 59:197  
 Lichtermann, D., 59:7  
 Liebowitz, M.R., 58:127  
 Lim, K.O., 60:125  
 Lipsitz, J.D., 56:173  
  
 Lish, J.D., 57:169  
 Loas, G., 60:57  
 Lohr, J.B., 57:279  
 Lombardi, J., 60:87  
 Löö, H., 57:41  
 Losonczy, M., 57:109  
 Lovell, B.B., 57:7  
 Lupien, S., 58:23  
 Luque, R., 56:183  
 Lyons, M.J., 56:135  
 Lysaker, P., 56:45  
  
 Macher, J.-P., 60:23  
 Maciejewski, P.K., 59:65  
 Maes, M., 58:89, 58:217  
 Maestri, D., 58:153  
 Maier, W., 59:7  
 Maina, G., 57:49  
 Mallet, J., 59:1  
 Manfredi, B., 59:43, 59:51  
 Marder, S.R., 57:155  
 Marin, D.B., 58:181  
 Marler, M., 57:21  
 Martin, J.R., 57:181  
 Martinez, M., 59:1, 59:25  
 Martinez, J., 58:127  
 Mauguère, F., 60:101  
 Mayo, A.L., 56:17  
 Mayor, J., 56:221  
 McCarthy, G., 59:97  
 McElroy, S.L., 57:209  
 McGarvey, K., 60:33  
 McGinn, L.K., 60:191  
 McIntosh, A.R., 57:119  
 McKenna, P.J., 56:183  
 Meares, R., 56:229, 56:237, 58:69  
 Medoff, D.R., 57:75, 58:53, 59:221  
 Meesters, Y., 57:223  
 Meltzer, H.Y., 58:89, 58:217  
 Mercier, C., 60:205  
 Miewald, J.M., 57:91, 59:203  
 Miller, M.D., 56:17, 59:65  
 Millet, P., 60:101  
 Minges, J., 59:7  
 Mintz, J., 57:155  
 Mintz, L.I., 57:155  
 Mirow, A., 58:23  
 Mitropoulou, V., 57:109, 59:127, 60:49  
 Modai, I., 57:193  
 Mohs, R.C., 57:109, 58:181, 60:49  
 Mokrani, M.-C., 60:23  
 Möller, H.-J., 58:107  
 Montrose, D.M., 57:91, 59:203  
 Moore, T.C., 56:101  
 Moran, M.J., 59:221  
 Moreau, J.-L., 57:181  
 Morel, C., 56:245  
  
 Morris, L., 60:167  
 Morrison, R.L., 56:121  
 Moss, H.B., 59:35  
 Mueser, K.T., 56:121, 57:141, 59:213  
 Müller, H., 58:107  
 Mulsant, B.H., 60:117  
 Murphy, D.G.M., 57:119  
 Myers, F., 59:151  
 Myslobodsky, M.S., 58:259  
  
 Nasrallah, H.A., 57:57, 57:83  
 Naukkarinen, H., 58:145  
 Nelson, E.C., 58:117  
 Nerenberg, J., 59:171  
 Nevitt, J., 57:75  
 Newsom, J.T., 59:65  
 Nisenson, L., 56:25  
 Noorthoorn, E., 56:299  
 Northcutt, C., 56:59  
 Noyes, R., Jr., 57:1, 60:185  
  
 O'Brien, J., 57:131  
 O'Callaghan, E., 59:119  
 Oguz, H., 59:165  
 Oomen, H.A.P.C., 58:83  
 Oren, D.A., 59:151  
 Orsulak, P.J., 60:41  
 Osgood, G., 57:131  
 Otto, M., 56:81  
 Ozaki, N., 59:151  
  
 Panchalingam, K.S., 57:91  
 Panerai, A.E., 59:43, 59:51  
 Panksepp, J., 58:191  
 Paradis, C.F., 56:17  
 Parker, J.D.A., 58:139  
 Parrella, M., 60:87  
 Pasternak, R., 60:117  
 Patralia, A., 56:295  
 Pazzaglia, P.J., 57:259  
 Peiper, S.C., 59:197  
 Peirone, A., 59:43, 59:51  
 Penn, D.L., 59:213  
 Pepple, J.R., 56:135  
 Peralta, V., 58:45, 58:227  
 Perel, J.M., 56:17  
 Perez, E., 60:1  
 Perl, M., 58:13  
 Perna, G., 57:267, 59:43, 59:51  
 Perry, S.W., 59:245  
 Peterson, E., 58:1  
 Petit, M., 59:1, 59:25  
 Pettigrew, J.W., 57:91  
 Pettigrew, G., 56:237, 58:69  
 Petty, F., 59:127, 60:41  
 Pfefferbaum, A., 60:125  
 Pigache, R.M., 60:155

- Piketty, M.L., 57:41  
 Plumet, M.-H., 58:191  
 Pohl, R., 56:289  
 Poirier, M.-F., 57:41  
 Ponds, R., 56:299  
 Post, R.M., 57:259  
 Powchik, P., 60:87  
 Preußler, 58:107  
 Priebe, S., 58:77  
 Prigerson, H.G., 59:65  
  
 Raeburn, S., 58:13  
 Ragland, J.D., 60:135  
 Raine, A., 56:71, 57:241  
 Räsänen, M., 58:145  
 Ramesh, C., 56:289  
 Randall, P., 59:97  
 Rao, M.L., 57:21  
 Rapaport, M., 58:99  
 Rapisarda, V., 56:295  
 Rapoport, J.L., 60:67  
 Rappe, S.M., 56:205  
 Ravizza, L., 57:49  
 Recasens, C., 58:191  
 Rechlin, T., 56:279  
 Reichelt, K.L., 58:171  
 Reist, C., 57:197, 57:275, 59:189, 60:177  
 Rémi-Bouissière, P., 57:41  
 Rennie, C., 56:229, 56:237, 58:69  
 Reynolds, C.F. III, 56:17, 57:91, 59:65, 59:203  
 Rice, J., 56:221  
 Richter, R., 58:23  
 Rifai, A.H., 56:17  
 Riordan, H., 60:167  
 Risch, S.C., 58:23  
 Ritzl, E.K., 57:75  
 Roberts, C.R., 58:237  
 Rochet, T., 60:205  
 Roemer, R.A., 58:247  
 Röhricht, F., 58:77  
 Rommelspacher, H., 56:81  
 Röschke, J., 56:257  
 Roseman, C., 57:251  
 Rosenthal, N.E., 59:151  
 Ross, D.E., 58:53, 59:221  
 Rossiter, E.M., 58:13  
 Rotter, M., 57:109  
 Rubin, S.A., 56:33  
 Rubinow, D., 57:259  
 Robinson, E., 60:191  
 Ruiz, J., 59:145  
 Rush, A.J., 60:41  
 Rusinek, H., 60:91  
 Ryan, T.M., 58:181  
  
 Sacerdote, P., 59:43, 59:51  
 Samolyk, D., 59:1  
  
 Samson, J.A., 56:25  
 Saoud, J.B., 58:161  
 Sarova-Pinchas, I., 58:177  
 Sayers, S.L., 56:121  
 Scarone, S., 58:37  
 Scarvalone, P.A., 59:245  
 Schaltenbrand, N., 60:23  
 Schapiro, M.B., 57:119  
 Scharpé, S., 58:217  
 Schild, K., 60:199  
 Schildkraut, J.J., 56:25  
 Schmeidler, J., 58:181  
 Schmidtke, A., 59:17  
 Schneider, J.A., 58:13  
 Schott, K., 59:251  
 Schultz, L., 58:1  
 Schwartz, P.J., 59:151  
 Scott, T.M., 59:97  
 Seidman, L.J., 56:135  
 Sevush, S., 59:145  
 Shapleske, J., 56:183  
 Sheline, Y.I., 58:117  
 Sheppard, N.P., 59:119  
 Siever, L.J., 57:109, 59:127, 60:49  
 Sikora, J., 59:161  
 Silverman, J., 57:109, 59:127  
 Sim, C.-B., 57:65  
 Simeon, D., 58:161  
 Simkowitz, P., 60:91  
 Singer, J., 58:259  
 Smeenk, R.J.T., 58:83  
 Smeraldi, E., 58:265  
 Smith, G., 60:91  
 Sofuoglu, S., 59:165  
 Sokolski, K.N., 57:197  
 Spaulding, W., 59:213  
 Spielman, L.A., 59:245  
 Srinivasan, K., 56:289, 60:77  
 Srisurapanont, M., 60:33  
 Stack, J.A., 56:17  
 Stein, D.J., 58:161  
 Stein, M.A., 57:13  
 Stein, M.B., 59:183  
 Stern, M., 58:259  
 Stöber, G., 59:17  
 Strakowski, S.M., 57:209  
 Strebel, B., 57:21  
 Sturm, Y., 58:107  
 Stygall, J., 56:71  
 Sullivan, E.V., 60:125  
 Summerfelt, A., 56:33  
 Sunderland, T., 57:259  
 Sutton, L., 58:99  
 Swedo, S.E., 60:67  
 Sweet, R.A., 60:117  
  
 Tabuteau, F., 58:191  
  
 Tagliavini, P., 58:153  
 Tamminga, C.A., 57:75, 58:53  
 Tang, S.W., 57:275, 59:189, 60:177  
 Teichberg, D., 57:119  
 Teigland-Gjerstad, B., 58:171  
 Telch, C.F., 58:13  
 Teng, C.T., 56:11  
 Terra, J.-L., 60:205  
 Thaker, G.K., 58:53, 59:221  
 Thibaut, F., 59:25, 59:1  
 Thomson, C., 57:241  
 Thornes, K., 56:1  
 Tierney, A.M., 56:121  
 Tompson, M.C., 57:155  
 Torello, M.W., 57:57, 57:83  
 Trestman, R.L., 57:109, 59:127  
 Trivedi, M., 60:41  
 True, J.E., 56:101  
 Tsai, S.-J., 57:65  
 Tseng, Y.-T., 57:101  
 Tsuang, M.T., 56:135  
 Tucker, H.A., 56:221  
 Tuckwell, H.C., 59:239  
 Tuetting, P.A., 57:83  
  
 Unis, A.S., 57:13  
  
 Valdivieso, S., 60:23  
 Valevski, A., 57:193  
 van Engeland, H., 58:203  
 Vanelle, J.-M., 57:41  
 van Kammen, D.P., 60:11  
 Vanyukov, M.M., 59:35  
 Velligan, D.I., 56:101  
 Vieira, A.H.G., 56:11  
 Viret, J., 59:255  
 Virkkunen, M., 58:145  
 Vogler, G.P., 56:213  
 Volavka, J., 59:161  
 Volkow, N.D., 60:91, 60:167  
 Volz, H.-P., 58:107  
 Vu, R., 57:275, 59:189  
  
 Wade, J.H., 56:121  
 Waller-Perotte, D., 58:191  
 Waltrip, R.W. II, 56:33  
 Wang, G.-J., 60:167  
 Weijnen, F.G., 58:203  
 Weinberger, D.R., 56:53, 56:155  
 Weis, M., 56:279  
 Weiss, K.M., 60:147  
 Weissman, M.M., 57:169  
 Weizman, A., 57:193  
 Wekking, E.M., 58:83  
 West, J., 56:205  
 White, L., 60:87  
 Wieneke, M., 60:167

Wildenauer, D., 59:7  
Willemssen-Swinkels, S.H.N., 58:203  
Wolf, J., 59:171  
Wolf, A.P., 60:91  
Wolfe, V., 56:59  
Wolkin, A., 60:91  
Woodman, C., 57:1  
Wormstall, H., 59:251  
Wu, S., 57:57, 57:83

Yang, Y.-C., 57:65  
Yao, J.K., 60:11  
Yatham, L.N., 60:33  
Yeragani, V.K., 56:289, 60:77  
Young, L.T., 58:139  
Yu, L.M., 59:35

Zahn, T.P., 60:67  
Zaimovic, A., 58:153  
Zarcone, V.P., Jr., 60:125  
Zemishlany, Z., 57:109  
Zhang-Wong, J., 59:109  
Zill, P., 59:7  
Zis, A.P., 60:33  
Zubenko, G.S., 60:117

the 1990s, the number of people in the world who are undernourished has increased from 600 million to 800 million (FAO 1996). The number of people who are malnourished has increased from 1.2 billion to 1.5 billion (FAO 1996).

There are a number of reasons why the number of people who are undernourished has increased. One of the main reasons is that the world population has increased. The world population is now over 6 billion, and it is expected to reach 9 billion by the year 2050. This means that there are more people in the world who need food. Another reason is that the world's food supply is not increasing fast enough to keep up with the growing population. This is because the world's food supply is based on a few crops, such as wheat, rice, and corn, which are grown in a few countries. This means that if there is a problem with the food supply in one of these countries, it can affect the whole world.

There are also a number of other factors that contribute to the problem of food insecurity. For example, the world's food supply is often affected by natural disasters, such as droughts and floods. These disasters can destroy crops and livestock, and can also damage infrastructure, such as roads and bridges. This can make it difficult for people to get food. Another factor is that the world's food supply is often affected by political instability. For example, if there is a war in a country, it can be difficult for people to get food. This is because the government may be unable to provide food, and because the country may be cut off from the world's food supply.

There are a number of ways that we can help to solve the problem of food insecurity. One way is to increase the world's food supply. This can be done by growing more crops, and by using more efficient farming methods. Another way is to improve the world's infrastructure, such as roads and bridges. This can make it easier for people to get food. A third way is to provide food aid to people who are in need. This can be done by giving them food, or by giving them money to buy food. There are also a number of other ways that we can help to solve the problem of food insecurity, such as by providing education and training to people who are in need.

There are a number of organizations that are working to solve the problem of food insecurity. For example, the United Nations World Food Programme (WFP) is a leading organization that provides food aid to people who are in need. The WFP also works to improve the world's food supply, and to provide education and training to people who are in need. There are also a number of other organizations that are working to solve the problem of food insecurity, such as the International Fund for Agricultural Development (IFAD) and the Food and Agriculture Organization (FAO).

There are a number of things that we can do to help to solve the problem of food insecurity. For example, we can donate money to organizations that are working to solve the problem. We can also volunteer our time to help these organizations. We can also try to eat more food that is produced locally, and we can try to reduce our food waste. There are a number of other things that we can do to help to solve the problem of food insecurity, and we all have a role to play in solving this problem.

## Subject index for 1995

### Adrenocorticotrophic hormone

affective disorder, cortisol, 59:157

### Affective disorder

age, cognition, 60:87  
 age disorientation, bipolar subtype, 60:87  
 age disorientation, cognition, 60:87  
 age disorientation, late-life depression, 60:87  
 age, interpersonal psychotherapy, 56:17  
 age, magnetic resonance imaging, 60:117  
 age, treatment outcome, 56:17  
 age, white matter hyperintensity, 60:117  
 anhedonia, bipolar subtype, 56:163  
 anhedonia, endogenomorphic subtype, 60:57  
 anhedonia, laterality, 56:163  
 anhedonia, skin conductance, 56:163  
 anticholinergic agent, sleep, rapid eye movement, 58:99  
 antidepressant effect, *S*-adenosyl-L-methionine, 56:295  
 anxiety disorder, comorbidity, 59:57  
 Arden ratio, circadian rhythm, 57:197  
 Arden ratio, sleep, 57:197  
 Arden ratio, sleep deprivation, 57:197  
 atypical depression, cortisol, 60:191  
 atypical depression, desipramine, 60:191  
 atypical depression, norepinephrine, 60:191  
 biperiden, sleep, rapid eye movement, 58:99  
 bipolar subtype, age disorientation, 60:87  
 bipolar subtype, anhedonia, 56:163  
 bipolar subtype, calcium pump, 59:197  
 bipolar subtype, cerebrospinal fluid protein, 57:259  
 bipolar subtype, chromosome 18, 59:7  
 bipolar subtype, cognition, 60:87  
 bipolar subtype, dopamine- $\beta$ -hydroxylase, 59:165  
 bipolar subtype, expressed emotion, 56:299  
 bipolar subtype, family therapy, 56:299  
 bipolar subtype, genetics, 59:7  
 bipolar subtype, harm avoidance, 57:209, 58:139  
 bipolar subtype, ion channels, 59:197  
 bipolar subtype, laterality, 56:163, 57:279  
 bipolar subtype, linkage analysis, 59:7  
 bipolar subtype, lithium, 59:165  
 bipolar subtype, lymphoblast cells, 59:197  
 bipolar subtype, monoamine oxidase, 59:165  
 bipolar subtype, motor activity, 57:279

bipolar subtype, negative symptoms, 56:145  
 bipolar subtype, novelty seeking, 58:139  
 bipolar subtype, pain, 56:173  
 bipolar subtype, personality, 57:209  
 bipolar subtype, psychoeducation, 56:299  
 bipolar subtype, sex, 57:259  
 bipolar subtype, signal detection, 56:173  
 bipolar subtype, skin conductance, 56:163  
 bipolar subtype, sodium pump, 59:197  
 bipolar subtype, stimulus intensity, 56:173  
 bipolar subtype, suicidality, 59:57  
 bipolar subtype, transmembrane potential, 59:197  
 bipolar subtype, Tridimensional Personality Questionnaire, 57:209, 58:139  
 bipolar subtype vs. unipolar subtype, 58:139, 59:57  
 brofaromine, late-life depression, 58:107  
 brofaromine, response prediction, 58:107  
 calcium pump, bipolar subtype, 59:197  
 calcium pump, ion channels, 59:197  
 calcium pump, lymphoblast cells, 59:197  
 calcium pump, transmembrane potential, 59:197  
 carbohydrate craving, circannual rhythm, 59:171  
 carbohydrate craving, light therapy, 59:171  
 carbohydrate craving, seasonal affective disorder, 59:171  
 carbohydrate craving, taste detection, 59:171  
 cerebrospinal fluid protein, bipolar subtype, 57:259  
 cerebrospinal fluid protein, sex, 57:259  
 chromosome 18, bipolar subtype, 59:7  
 chromosome 18, linkage analysis, 59:7  
 circadian rhythm, Arden ratio, 57:197  
 circadian rhythm, electrooculography, 57:197  
 circadian rhythm, light therapy, 56:221  
 circadian rhythm, melatonin, 56:221  
 circadian rhythm, photoperiod, 60:199  
 circadian rhythm, seasonal affective disorder, 56:221  
 circadian rhythm, sleep, sleep deprivation, 57:197  
 circadian rhythm, violence, 60:199  
 circadian rhythm, visual adaptation, 57:197  
 circannual rhythm, carbohydrate craving, 59:171  
 circannual rhythm, electrooculography ratio, 59:151  
 circannual rhythm, ethology, 57:223  
 circannual rhythm, light therapy, 56:111, 56:221, 57:223, 59:171  
 circannual rhythm, melatonin, 56:221  
 circannual rhythm, photoperiod, 60:199

- circannual rhythm, retina, 59:151  
 circannual rhythm, seasonal affective disorder, 56:11, 56:221, 57:223, 59:151, 59:171  
 circannual rhythm, Southern Hemisphere, 56:11  
 circannual rhythm, taste detection, 59:171  
 circannual rhythm, violence, 60:199  
 clonidine, growth hormone, 60:23  
 cognition, age disorientation, 60:87  
 comorbidity, anxiety disorder, 59:57  
 comorbidity, epidemiology, 59:57  
 comorbidity, panic disorder, 59:57  
 computed tomography, cortisol, 59:157  
 cortisol, atypical depression, 60:191  
 cortisol, computed tomography, 59:157  
 cortisol, desipramine, 60:191  
 cortisol, dexamethasone, 60:23  
 delirium, amitriptyline, 56:279  
 desipramine, atypical depression, 60:191  
 desipramine, norepinephrine, 60:191  
 dexamethasone, cortisol, 60:23  
 diagnosis, outcome, 59:109  
 dopamine- $\beta$ -hydroxylase, monoamine oxidase, 59:165  
 elderly patients, magnetic resonance imaging, 60:117  
 elderly patients, white matter hyperintensity, 60:117  
 electroencephalography, period analysis, 56:245  
 electroencephalography, power spectral-analysis, 56:245  
 electroencephalography, sleep, 56:245  
 electrooculography, Arden ratio, 57:197  
 electrooculography, circadian rhythm, 57:197, 59:151  
 electrooculography, retina, 59:151  
 electrooculography, seasonal affective disorder, 59:151  
 electrooculography, sleep, sleep deprivation, 57:197  
 electrooculography, visual adaptation, 57:197  
 endogenomorphic subtype, anhedonia, 60:57  
 epidemiology, comorbidity, 59:57  
 epidemiology, genetics, 57:169  
 epidemiology, sex, 58:1  
 epidemiology, suicidality, 59:57  
 ethology, circannual rhythm, 57:223  
 ethology, light therapy, 57:223  
 ethology, seasonal affective disorder, 57:223  
 expressed emotion, bipolar subtype, 56:299  
 expressed emotion, family therapy, 56:299  
 expressed emotion, psychoeducation, 56:299  
 family therapy, bipolar subtype, 56:299  
 family therapy, expressed emotion, 56:299  
 family therapy, psychoeducation, 56:299  
 Family History Screen for Epidemiologic Studies, genetics, 57:169  
 fluoxetine, mania, 58:217  
 fluoxetine, prolyl endopeptidase, 58:217  
 fluoxetine, valproate, 58:217  
 genetics, bipolar subtype, 59:7  
 genetics, chromosome 18, 59:7  
 genetics, Family History Screen for Epidemiologic Studies, 57:169  
 genetics, linkage analysis, 59:7  
 growth hormone, clonidine, 60:23  
 harm avoidance, bipolar subtype, 57:209, 58:139  
 harm avoidance, Tridimensional Personality Questionnaire, 57:209, 58:139  
 harm avoidance, unipolar subtype, 58:139  
 heart rate, amitriptyline, 56:279  
 heart rate, delirium, 56:279  
 imipramine, late-life depression, 58:107  
 imipramine, pharmacokinetics, 59:189  
 imipramine, response prediction, 58:107  
 interpersonal psychotherapy, late-life depression, 56:17  
 interpersonal psychotherapy, nortriptyline, 56:17  
 interpersonal psychotherapy, recruitment method, 56:17  
 interpersonal psychotherapy, treatment outcome, 56:17  
 ion channels, bipolar subtype, 59:197  
 ion channels, calcium pump, 59:197  
 ion channels, lymphoblast cells, 59:197  
 ion channels, sodium pump, 59:197  
 ion channels, transmembrane potential, 59:197  
 late-life depression, age disorientation, 60:87  
 late-life depression, brofaromine, 58:107  
 late-life depression, cognition, 60:87  
 late-life depression, imipramine, 58:107  
 late-life depression, interpersonal psychotherapy, 56:17  
 late-life depression, magnetic resonance imaging, 60:117  
 late-life depression, monoamine oxidase inhibitor, 58:107  
 late-life depression, nortriptyline, 56:17  
 late-life depression, recruitment method, 56:17  
 late-life depression, response prediction, 58:107  
 late-life depression, treatment outcome, 56:17  
 late-life depression, white matter hyperintensity, 60:117  
 laterality, bipolar subtype, 56:163, 57:279  
 laterality, motor activity, 57:279  
 laterality, skin conductance, 56:163  
 light therapy, carbohydrate craving, 59:171  
 light therapy, circadian rhythm, 56:221  
 light therapy, circannual rhythm, 56:11, 56:221, 57:223, 59:171  
 light therapy, melatonin, 56:221  
 light therapy, seasonal affective disorder, 56:11, 56:221, 57:223, 59:171  
 linkage analysis, bipolar subtype, 59:7  
 linkage analysis, chromosome 18, 59:7  
 lithium, bipolar subtype, 59:165  
 lymphoblast cells, bipolar subtype, 59:197  
 lymphoblast cells, calcium pump, 59:197  
 lymphoblast cells, ion channels, 59:197  
 lymphoblast cells, sodium pump, 59:197  
 lymphoblast cells, transmembrane potential, 59:197  
 magnetic resonance imaging, age, 60:117  
 magnetic resonance imaging, late-life depression, 60:117  
 magnetic resonance imaging, white matter hyperintensity, 60:117  
 mania, fluoxetine, 58:217  
 mania, peptides, 58:217  
 mania, prolyl endopeptidase, 58:217  
 mania, valproate, 58:217  
 melatonin, circadian rhythm, 56:221



- melatonin, circannual rhythm, 56:221  
 melatonin, light therapy, 56:221  
 melatonin, seasonal affective disorder, 56:221  
 monoamine oxidase, bipolar subtype, 59:165  
 monoamine oxidase inhibitor, late-life depression, 58:107  
 monoamine oxidase inhibitor, response prediction, 58:107  
 monoamine oxidase, platelets, 59:165  
 motor activity, bipolar subtype, 57:279  
 motor activity, laterality, 57:279  
 negative symptoms, transitory nature, 56:145  
 norepinephrine, atypical depression, 60:191  
 norepinephrine, desipramine, 60:191  
 nortriptyline, age, 56:17  
 nortriptyline, interpersonal psychotherapy, 56:17  
 nortriptyline, late-life depression, 56:17  
 nortriptyline, treatment outcome, 56:17  
 novelty seeking, bipolar subtype, 58:139  
 novelty seeking, Tridimensional Personality Questionnaire, 58:139  
 novelty seeking, unipolar subtype, 58:139  
 ondansetron, prolactin, 60:33  
 ondansetron, serotonin, 60:33  
 outcome, diagnosis, 59:109  
 pain, bipolar subtype, 56:173  
 pain, signal detection, 56:173  
 pain, stimulus intensity, 56:173  
 paroxetine binding, platelet, 58:117  
 paroxetine, serotonin, 58:117, 59:189  
 peptides, mania, 58:217  
 personality, bipolar subtype, 57:209  
 pharmacokinetics, imipramine, 59:189  
 polysomnography, period analysis, 56:245  
 polysomnography, power spectral analysis, 56:245  
 prognosis, presence of negative symptoms in first episode, 56:145  
 prolactin, ondansetron, 60:33  
 prolyl endopeptidase, mania, 58:217  
 protein, cerebrospinal fluid, 57:259  
 protein, sex, 57:259  
 psychoeducation, bipolar subtype, 56:299  
 psychoeducation, expressed emotion, 56:299  
 psychoeducation, family therapy, 56:299  
 rapid eye movement, anticholinergic agent, 58:99  
 rapid eye movement, biperiden, 58:99  
 response prediction, brofaromine, 58:107  
 response prediction, imipramine, 58:107  
 response prediction, late-life depression, 58:107  
 response prediction, monoamine oxidase inhibitor, 58:107  
 retina, circannual rhythm, 59:151  
 retina, electrooculography, 59:151  
 retina, seasonal affective disorder, 59:151  
 S-adenosyl-L-methionine, antidepressant effect, 56:295  
 seasonal affective disorder, carbohydrate craving, 59:171  
 seasonal affective disorder, circadian rhythm, 56:221  
 seasonal affective disorder, circannual rhythm, 56:11, 56:221, 57:223, 59:151, 59:171  
 seasonal affective disorder, electrooculography, 59:151  
 seasonal affective disorder, ethology, 57:223  
 seasonal affective disorder, light therapy, 56:221, 57:223, 59:171  
 seasonal affective disorder, melatonin, 56:221  
 seasonal affective disorder, retina, 59:151  
 seasonal affective disorder, Southern Hemisphere, 56:11  
 seasonal affective disorder, taste detection, 59:171  
 serotonin, ondansetron, 60:33  
 serotonin, paroxetine, 58:117, 59:189  
 serotonin, platelet, 58:117  
 serotonin, prolactin, 60:33  
 sex, bipolar subtype, 57:259  
 sex, epidemiology, 58:1  
 sex, protein, 57:259  
 signal detection, bipolar subtype, 56:173  
 signal detection, pain, 56:173  
 signal detection, stimulus intensity, 56:173  
 skin conductance, anhedonia, 56:163  
 skin conductance, bipolar subtype, 56:163  
 skin conductance, laterality, 56:163  
 sleep, anticholinergic agent, 58:99  
 sleep, biperiden, 58:99  
 sleep, circadian rhythm, 57:197  
 sleep deprivation, Arden ratio, 57:197  
 sleep deprivation, circadian rhythm, 57:197  
 sleep deprivation, electrooculography, 57:197  
 sleep deprivation, visual adaptation, 57:197  
 sleep, electroencephalography, 56:245  
 sleep, electrooculography, 57:197  
 sleep, period analysis, 56:245  
 sleep, polysomnography, 56:245  
 sleep, power spectral analysis, 56:245  
 sleep, rapid eye movement, 58:99  
 sleep, visual adaptation, 57:197  
 sodium pump, bipolar subtype, 59:197  
 sodium pump, ion channels, 59:197  
 sodium pump, lymphoblast cells, 59:197  
 sodium pump, transmembrane potential, 59:197  
 stimulus intensity, pain, 56:173  
 stimulus intensity, signal detection, 56:173  
 suicidality, bipolar subtype, 59:57  
 suicidality, epidemiology, 59:57  
 suicidality, unipolar subtype, 59:57  
 taste detection, carbohydrate craving, 59:171  
 taste detection, circannual rhythm, 59:171  
 taste detection, light therapy, 59:171  
 taste detection, seasonal affective disorder, 59:171  
 thyroid hormones, 57:41, 57:41  
 thyroid-stimulating hormone, thyrotropin-releasing hormone, 57:41  
 thyrotropin-releasing hormone, thyroid-stimulating hormone, 57:41  
 transmembrane potential, bipolar subtype, 59:197  
 transmembrane potential, calcium pump, 59:197  
 transmembrane potential, ion channels, 59:197  
 transmembrane potential, lymphoblast cells, 59:197  
 transmembrane potential, sodium pump, 59:197  
 treatment outcome, age, 56:17  
 treatment outcome, interpersonal psychotherapy, 56:17  
 treatment outcome, late-life depression, 56:17

treatment outcome, nortriptyline, 56:17  
 Tridimensional Personality Questionnaire, bipolar subtype, 57:209, 58:139  
 Tridimensional Personality Questionnaire, harm avoidance, 57:209, 58:139  
 Tridimensional Personality Questionnaire, novelty seeking, 58:139  
 Tridimensional Personality Questionnaire, unipolar subtype, 58:139  
 unipolar subtype, epidemiology, 59:57  
 unipolar subtype, harm avoidance, 58:139  
 unipolar subtype, novelty seeking, 58:139  
 unipolar subtype, suicidality, 59:57  
 unipolar subtype, Tridimensional Personality Questionnaire, 58:139  
 unipolar subtype vs. bipolar subtype, 58:139, 59:57  
 valproate, mania, 58:217  
 valproate, prolidase, 58:217  
 violence, circadian rhythm, 60:199  
 violence, circannual rhythm, 60:199  
 violence, photoperiod, 60:199  
 visual adaptation, Arden ratio, 57:197  
 visual adaptation, circadian rhythm, 57:197  
 visual adaptation, electrooculography, 57:197  
 white matter hyperintensity, age, 60:117  
 white matter hyperintensity, late-life depression, 60:117  
 white matter hyperintensity, magnetic resonance imaging, 60:117

# Age

affective disorder, age disorientation, 60:87  
 affective disorder, cognition, 60:87  
 affective disorder, interpersonal psychotherapy, 56:17  
 affective disorder, magnetic resonance imaging, 60:117  
 affective disorder, schizophrenia, 60:117  
 affective disorder, treatment outcome, 56:17  
 affective disorder, white matter hyperintensity, 60:117  
 age disorientation, affective disorder, 60:87  
 age disorientation, bipolar subtype, 60:87  
 age disorientation, cognition, 60:87  
 age disorientation, late-life depression, 60:87  
 Alzheimer's Disease, brain volume, 57:119  
 Alzheimer's Disease, magnetic resonance imaging, 57:119  
 Alzheimer's Disease, sex, 57:119  
 Alzheimer's Disease, temporal lobe, 57:119  
 bipolar affective disorder, age disorientation, 60:87  
 bipolar affective disorder, cognition, 60:87  
 brain volume, Alzheimer's Disease, 57:119  
 brain volume, dementia, 57:119  
 brain volume, magnetic resonance imaging, 57:119  
 brain volume, temporal lobe, 57:119  
 cognition, age disorientation, 60:87  
 cognition, late-life depression, 60:87  
 dementia, brain volume, 57:119  
 dementia, magnetic resonance imaging, 57:119  
 dementia, temporal lobe, 57:119  
 interpersonal psychotherapy, late-life depression, 56:17  
 interpersonal psychotherapy, treatment outcome, 56:17

late-life depression, magnetic resonance imaging, 60:117  
 late-life depression, white matter hyperintensity, 60:117  
 late-life depression, interpersonal psychotherapy, 56:17  
 late-life depression, nortriptyline, 56:17  
 late-life depression, treatment outcome, 56:17  
 late-life depression, age disorientation, 60:87  
 late-life depression, cognition, 60:87  
 magnetic resonance imaging, affective disorder, 60:117  
 magnetic resonance imaging, Alzheimer's Disease, 57:119  
 magnetic resonance imaging, brain volume, 57:119  
 magnetic resonance imaging, dementia, 57:119  
 magnetic resonance imaging, elderly patients, 60:117  
 magnetic resonance imaging, late-life depression, 60:117  
 magnetic resonance imaging, schizophrenia, 60:117  
 magnetic resonance imaging, temporal lobe, 57:119  
 magnetic resonance imaging, white matter hyperintensity, 60:117  
 nortriptyline, interpersonal psychotherapy, 56:17  
 nortriptyline, late-life depression, 56:17  
 nortriptyline, treatment outcome, 56:17  
 schizophrenia, elderly patients, 60:117  
 schizophrenia, magnetic resonance imaging, 60:117  
 schizophrenia, white matter hyperintensity, 60:117  
 sex, Alzheimer's Disease, 57:119  
 sex, dementia, 57:119  
 temporal lobe, Alzheimer's Disease, 57:119  
 temporal lobe, brain volume, 57:119  
 temporal lobe, dementia, 57:119  
 temporal lobe, magnetic resonance imaging, 57:119  
 treatment outcome, geriatric psychiatry, 56:17  
 treatment outcome, late-life depression, 56:17  
 white matter hyperintensity, late-life depression, 60:117  
 white matter hyperintensity, magnetic resonance imaging, 60:117  
 white matter hyperintensity, schizophrenia, 60:117

# Agoraphobia. See Anxiety disorder; Panic disorder

# Aggression

anger attacks, anorexia, bulimia, 56:205  
 anorexia, anger attacks, 56:205  
 bulimia, anger attacks, 56:205  
 conduct disorder, dinucleotide repeat polymorphism, 59:35  
 conduct disorder, genetics, 59:35  
 conduct disorder, monoamine oxidase, 59:35  
 conduct disorder, personality, 59:35  
 conduct disorder, polymerase chain reaction, 59:35  
 dinucleotide repeat polymorphism, conduct disorder, 59:35  
 dinucleotide repeat polymorphism, genetics, 59:35  
 dinucleotide repeat polymorphism, monoamine oxidase, 59:35  
 dinucleotide repeat polymorphism, personality, 59:35  
 dinucleotide repeat polymorphism, polymerase chain reaction, 59:35  
 eating disorder, anger attacks, 56:205  
 genetics, conduct disorder, 59:35  
 genetics, dinucleotide repeat polymorphism, 59:35  
 genetics, monoamine oxidase, 59:35

genetics, personality, 59:35  
 genetics, polymerase chain reaction, 59:35  
 monoamine oxidase, conduct disorder, 59:35  
 monoamine oxidase, dinucleotide repeat polymorphism, 59:35  
 monoamine oxidase, genetics, 59:35  
 monoamine oxidase, personality, 59:35  
 monoamine oxidase, polymerase chain reaction, 59:35  
 personality, dinucleotide repeat polymorphism, 59:35  
 personality, genetics, 59:35  
 personality, monoamine oxidase, 59:35  
 personality, polymerase chain reaction, 59:35  
 polymerase chain reaction, dinucleotide repeat polymorphism, 59:35  
 polymerase chain reaction, monoamine oxidase, 59:35  
 polymerase chain reaction, personality, 59:35

#### **Alcohol dependence**

abstinence, blood pressure, 59:137  
 abstinence, cortisol, 56:81  
 abstinence,  $\gamma$ -aminobutyric acid, 59:137  
 abstinence, heart rate, 59:137  
 abstinence, hypothalamic-pituitary-gonadal axis, 56:81  
 abstinence, liver function, 59:137  
 abstinence, prolactin, 56:81  
 anxiety, abstinence, 59:137  
 anxiety, blood pressure, 59:137  
 anxiety,  $\gamma$ -aminobutyric acid, 59:137  
 anxiety, heart rate, 59:137  
 anxiety, liver function, 59:137  
 blood pressure, abstinence, 59:137  
 blood pressure, anxiety, 59:137  
 blood pressure,  $\gamma$ -aminobutyric acid, 59:137  
 calcium, intracellular, 57:275  
 calcium, serotonin, 57:275  
 cortisol, abstinence, 56:81  
 $\gamma$ -aminobutyric acid, abstinence, 59:137  
 $\gamma$ -aminobutyric acid, anxiety, 59:137  
 $\gamma$ -aminobutyric acid, blood pressure, 59:137  
 $\gamma$ -aminobutyric acid, heart rate, 59:137  
 $\gamma$ -aminobutyric acid, liver function, 59:137  
 heart rate, abstinence, 59:137  
 heart rate, anxiety, 59:137  
 heart rate,  $\gamma$ -aminobutyric acid, 59:137  
 hypothalamic-pituitary-gonadal axis, abstinence, 56:81  
 liver function, abstinence, 59:137  
 prolactin, abstinence, 56:81  
 serotonin, intracellular calcium, 57:275

#### **Alzheimer's Disease**

autoantibody reactivity, dementia, 59:251  
 brain volume, discriminant analysis, 57:119  
 brain volume, magnetic resonance imaging, 57:119  
 brain volume, sex, 57:119  
 brain volume, temporal lobe, 57:119  
 cognition, deprenyl, 58:181  
 cognition, monoamine oxidase inhibitor, 58:181  
 cognition, physostigmine, 58:181  
 deprenyl, cognition, 58:181

discriminant analysis, brain volume, 57:119  
 discriminant analysis, magnetic resonance imaging, 57:119  
 evoked potentials, genetics, 57:57  
 evoked potentials, oddball paradigm, 57:57  
 evoked potentials, risk study, 57:57  
 genetics, evoked potentials, 57:57  
 genetics, risk study, 57:57  
 immunology, autoantibody reactivity, 59:251  
 magnetic resonance imaging, brain volume, 57:119  
 magnetic resonance imaging, discriminant analysis, 57:119  
 magnetic resonance imaging, sex, 57:119  
 magnetic resonance imaging, temporal lobe, 57:119  
 monoamine oxidase inhibitor, cognition, 58:181  
 neuroleptic effect, brain volume, 57:119  
 neuroleptic effect, magnetic resonance imaging, 57:119  
 physostigmine, cognition, 58:181  
 risk study, dementia, 57:57  
 risk study, evoked potentials, 57:57  
 risk study, genetics, 57:57  
 serotonin, dementia, 59:145  
 serotonin, platelets, 59:145  
 sex, age, 57:119  
 sex, brain volume, 57:119  
 sex, neuroleptic effect, 57:119  
 sex, temporal lobe, 57:119  
 temporal lobe, age, 57:119  
 temporal lobe, brain volume, 57:119  
 temporal lobe, magnetic resonance imaging, 57:119  
 temporal lobe, neuroleptic effect, 57:119  
 temporal lobe, sex, 57:119

#### **Amphetamine**

animal study, 2-deoxyglucose, 57:65  
 animal study, local cerebral glucose, 57:65  
 animal study, rat, 57:65

#### **Anger attacks**

aggression, anorexia, bulimia, 56:205  
 anorexia, aggression, 56:205  
 bulimia, aggression, 56:205  
 eating disorder, aggression, 56:205

#### **Anhedonia**

affective disorder, bipolar subtype, 56:163  
 affective disorder, laterality, 56:163  
 affective disorder, skin conductance, 56:163  
 bipolar affective disorder, laterality, 56:163  
 bipolar affective disorder, skin conductance, 56:163  
 laterality, bipolar affective disorder, 56:163  
 laterality, schizoaffective disorder, 56:163  
 laterality, schizophrenia, 56:163  
 laterality, skin conductance, 56:163  
 schizoaffective disorder, laterality, 56:163  
 schizoaffective disorder, skin conductance, 56:163  
 schizophrenia, laterality, 56:163  
 schizophrenia, skin conductance, 56:163  
 skin conductance, bipolar affective disorder, 56:163  
 skin conductance, laterality, 56:163

skin conductance, schizoaffective disorder, 56:163  
 skin conductance, schizophrenia, 56:163

#### Animal models and studies

alprazolam, anxiety disorder, 57:181  
 alprazolam, dorsal periaqueductal gray matter, 57:181  
 alprazolam, intracerebral stimulation, 57:181  
 alprazolam, panic disorder, 57:181  
 amphetamine, 2-deoxyglucose, 57:65  
 amphetamine, local cerebral glucose, 57:65  
 anxiety disorder, rat model, 57:181  
 apomorphine, dopamine, 58:165  
 apomorphine, phospholipase A2, 58:165  
 carbamazepine, circadian rhythm, hamster, 57:215  
 circadian rhythm, carbamazepine, hamster, 57:215  
 circadian rhythm, lithium, 57:215  
 circadian rhythm, valproate, 57:215  
 circadian rhythm, verapamil, 57:215  
 clonazepam, anxiety disorder, 57:181  
 clonazepam, panic disorder, 57:181  
 clonazepam, rat, 57:181  
 clonazepam, yohimbine, 57:181  
 2-deoxyglucose, amphetamine, rat, 57:65  
 dopamine, apomorphine, rat, 58:165  
 dopamine, phospholipase A2, rat, 58:165  
 dorsal periaqueductal gray matter, intracerebral stimulation, 57:181  
 dorsal periaqueductal gray matter, rat, 57:181  
 hamster, carbamazepine, 57:215  
 hamster, circadian rhythm, 57:215  
 hamster, lithium, 57:215  
 hamster, valproate, 57:215  
 hamster, verapamil, 57:215  
 intracerebral stimulation, dorsal periaqueductal gray matter, rat, 57:181  
 lithium, circadian rhythm, hamster, 57:215  
 local cerebral glucose, amphetamine, rat, 57:65  
 panic-anxiety disorder, rat model, 57:181  
 phospholipase A2, apomorphine, rat, 58:165  
 phospholipase A2, dopamine, rat, 58:165  
 rat, alprazolam, 57:181  
 rat, amphetamine, 57:65  
 rat, apomorphine, 58:165  
 rat, clonazepam, 57:181  
 rat, 2-deoxyglucose, 57:65  
 rat, dopamine, 58:165  
 rat, dorsal periaqueductal gray matter, 57:181  
 rat, intracerebral stimulation, 57:181  
 rat, local cerebral glucose, 57:65  
 rat, phospholipase A2, 58:165  
 rat, yohimbine, 57:181  
 valproate, circadian rhythm, hamster, 57:215  
 verapamil, circadian rhythm, hamster, 57:215  
 yohimbine, anxiety-panic model, rat, 57:181

Anorexia nervosa. *See* Eating disorder

#### Anticardiolipin antibody

dementia, immunology, 58:83  
 dementia, vascular signs, 58:83  
 immunology, dementia, 58:83  
 immunology, vascular signs, 58:83  
 vascular signs, dementia, 58:83  
 vascular signs, immunology, 58:83

#### Anxiety

human immunodeficiency virus, Structured Clinical Interview for DSM-III-R, 59:245  
 Structured Clinical Interview for DSM-III-R, human immunodeficiency virus, 59:245  
 visual analogue scale, human immunodeficiency virus, 59:245  
 visual analogue scale, Structured Clinical Interview for DSM-III-R, 59:245

Anxiety disorder. *See also* Obsessive-compulsive disorder; Panic disorder; Posttraumatic stress disorder; Social phobia

Acute Panic Inventory, lactate, 58:127  
 Acute Panic Inventory, panic attacks, 58:127  
 agoraphobia, carbon dioxide inhalation, 57:267  
 agoraphobia, panic attacks, 57:267  
 alprazolam, animal model of panic-anxiety, 57:181  
 animal model, dorsal periaqueductal gray matter, rat, 57:181  
 blood pressure, lactate-induced panic attacks, 58:127  
 carbon dioxide inhalation, agoraphobia, 57:267  
 carbon dioxide inhalation, panic attacks, 57:267  
 clonazepam, animal model of panic-anxiety, 57:181  
 diazepam, blood pressure, 58:127  
 diazepam, lactate-induced panic attacks, 58:127  
 epidemiology, genetics, 57:169  
 epidemiology, sex, 58:1  
 Family History Screen for Epidemiologic Studies, genetics, 57:169  
 genetics, Family History Screen for Epidemiologic Studies, 57:169  
 heart rate, isoproterenol, 56:289  
 heart rate, spectral analysis, 56:289  
 heart rate, sympathovagal ratio, 56:289  
 5-hydroxyindoleacetic acid, serotonin, 57:1  
 5-hydroxyindoleacetic acid, urinary measures, 57:1  
 isoproterenol, heart rate, 56:289  
 isoproterenol, panic disorder, 56:289  
 isoproterenol, sympathovagal ratio, 56:289  
 lactate infusion, Acute Panic Inventory, 58:127  
 lactate infusion, blood pressure, 58:127  
 lactate infusion, panic attacks, 58:127  
 N-acetyl- $\beta$ -glucosaminidase, anxiety, 60:185  
 neuropeptide Y, norepinephrine, 59:183  
 neuropeptide Y, stress, 59:183  
 norepinephrine, panic disorder, 59:183  
 norepinephrine, stress, 59:183  
 norepinephrine, urinary measures, 57:1  
 norepinephrine, vanillylmandelic acid, 57:1  
 panic attacks, Acute Panic Inventory, 58:127

panic attacks, agoraphobia, 57:267  
 panic attacks, blood pressure, 58:127  
 panic attacks, carbon dioxide inhalation, 57:267  
 panic attacks, diazepam, 58:127  
 panic attacks, lactate infusion, 58:127  
 peptides, panic disorder, 59:183  
 peptides, social phobia, 59:183  
 peptides, stress, 59:183  
 Profile of Mood States, *N*-acetyl- $\beta$ -glucosaminidase, 60:185  
 rat, panic-anxiety model, 57:181  
 serotonin, 5-hydroxyindoleacetic acid, 57:1  
 serotonin, urinary measures, 57:1  
 sex, epidemiology, 58:1  
 social phobia, neuropeptide Y, 59:183  
 social phobia, norepinephrine, 59:183  
 social phobia, stress, 59:183  
 stress, neuropeptide Y, 59:183  
 stress, norepinephrine, 59:183  
 stress, peptides, 59:183  
 sympathovagal ratio, isoproterenol, 56:289  
 sympathovagal ratio, panic disorder, 56:289  
 vanillylmandelic acid, norepinephrine, 57:1  
 vanillylmandelic acid, urinary measures, 57:1  
 yohimbine, animal model of panic-anxiety, 57:181

#### **Apomorphine**

dopamine, phospholipase A2, rat, 58:165  
 phospholipase A2, dopamine, rat, 58:165

#### **Arachidonic acid**

phospholipids, schizophrenia, 60:11  
 schizophrenia, phospholipids, 60:11

#### **Attention. See also Cognition. Neuropsychology**

Continuous Performance Test, distractibility, 57:131  
 Continuous Performance Test, neuroleptic effects, 57:131  
 Continuous Performance Test, schizophrenia, 57:131  
 disorganized symptoms, heart rate, 57:241  
 disorganized symptoms, schizoaffective disorder, 57:241  
 disorganized symptoms, schizophrenia, 57:241  
 evoked potentials, P300 component, 58:69  
 evoked potentials, reaction time, 58:69  
 evoked potentials, schizophrenia, 58:69  
 heart rate, skin conductance, 57:241  
 negative symptoms, schizoaffective disorder, 57:241  
 negative symptoms, schizophrenia, 57:241  
 neuroleptic effects, Continuous Performance Test, 57:131  
 neuroleptic effects, distractibility, 57:131  
 neuroleptic effects, schizophrenia, 57:131  
 positive symptoms, schizoaffective disorder, 57:241  
 positive symptoms, schizophrenia, 57:241  
 reaction time, evoked potentials, 58:69  
 reaction time, schizophrenia, 58:69  
 schizoaffective disorder, disorganized symptoms, 57:241  
 schizoaffective disorder, negative symptoms, 57:241  
 schizoaffective disorder, positive symptoms, 57:241

schizophrenia, Continuous Performance Test, 57:131  
 schizophrenia, disorganized symptoms, 57:241  
 schizophrenia, distractibility, 57:131  
 schizophrenia, evoked potentials, 58:69  
 schizophrenia, negative symptoms, 57:241  
 schizophrenia, neuroleptic effects, 57:131  
 schizophrenia, positive symptoms, 57:241  
 schizophrenia, reaction time, 58:69  
 schizophrenia, social cue perception, 56:111  
 schizophrenia, tone discrimination, 57:75  
 skin conductance, heart rate, 57:241  
 social cue perception, schizophrenia, 56:111  
 tone discrimination, schizophrenia, 57:75

#### **Attention deficit hyperactivity disorder**

attention, neuropsychology, Stroop test, 56:59  
 conduct disorder, genetics, 57:13  
 conduct disorder, serotonin, 57:13  
 genetics, conduct disorder, oppositional-defiant disorder, 57:13  
 genetics, serotonin, 57:13  
 neuropsychology, attention, 56:59  
 oppositional-defiant disorder, genetics, 57:13  
 oppositional-defiant disorder, serotonin, 57:13  
 serotonin, conduct disorder, oppositional-defiant disorder, 57:13  
 serotonin, genetics, 57:13  
 Stroop test, attention, 56:59

#### **Autism**

$\beta$ -endorphin, cortisol, 58:203  
 cortisol,  $\beta$ -endorphin, 58:203  
 naltrexone,  $\beta$ -endorphin, 58:191, 58:203  
 naltrexone, cortisol, 58:203  
 naltrexone, social behavior, 58:203  
 naltrexone, treatment response, 58:191, 58:203  
 social behavior, naltrexone, 58:203  
 treatment response to naltrexone, 58:191, 58:203

#### **Autonomic nervous system. See Blood pressure; Heart rate; Skin conductance**

#### **Baclofen**

$\gamma$ -aminobutyric acid, growth hormone, 60:41

#### **Behavior therapy**

agoraphobia, panic disorder, 56:1  
 alcohol abuse, 56:1  
 anxiety disorder, agoraphobia, 56:1  
 obsessive-compulsive disorder, 56:1  
 panic disorder, agoraphobia, 56:1  
 personality disorder, 56:1

#### **Bereavement**

depression, factor analysis, 59:65  
 depression, Inventory of Complicated Grief, 59:65  
 factor analysis, depression, 59:65

factor analysis, Inventory of Complicated Grief, 59:65  
Inventory of Complicated Grief, depression, 59:65  
Inventory of Complicated Grief, factor analysis, 59:65

**Beta-endorphin**

amineptine, anorexia, 59:43  
amineptine, bulimia, 59:51  
anorexia, amineptine, 59:43  
anorexia, cholecystokinin-8, 59:43  
anorexia, eating disorder, 59:43  
anorexia, fluoxetine, 59:43  
anorexia, peptides, 59:43  
autism, naltrexone, 58:191, 58:203  
autism, social behavior, 58:203  
bulimia, amineptine, 59:51  
bulimia, cholecystokinin-8, 59:51  
bulimia, fluvoxamine, 59:51  
bulimia, peptides, 59:51  
cholecystokinin-8, anorexia, 59:43  
cholecystokinin-8, bulimia, 59:51  
cortisol, naltrexone, 58:203  
eating disorder, amineptine, 59:43, 59:51  
eating disorder, cholecystokinin-8, 59:43, 59:51  
eating disorder, fluoxetine, 59:43  
eating disorder, fluvoxamine, 59:51  
eating disorder, peptides, 59:43, 59:51  
fluoxetine, anorexia, 59:43  
fluvoxamine, bulimia, 59:51  
naltrexone, autism, 58:191, 58:203  
naltrexone, social behavior, 58:203  
peptides, anorexia, 59:43  
peptides, bulimia, 59:51  
social behavior, autism, 58:203  
social behavior, naltrexone, 58:203

**Biperiden**

affective disorder, rapid eye movement, sleep, 58:99  
rapid eye movement, sleep, affective disorder, 58:99  
sleep, affective disorder, 58:99

**Bipolar affective disorder.** *See* Affective disorder (bipolar subtype)

**Blood pressure**

abstinence, alcohol dependence, 59:137  
alcohol dependence, abstinence, 59:137  
alcohol dependence, heart rate, 59:137  
anxiety, alcohol dependence, 59:137  
 $\gamma$ -aminobutyric acid, alcohol dependence, 59:137  
heart rate, alcohol dependence, 59:137  
lactate infusion, respiration, 60:77  
liver function, alcohol dependence, 59:137  
lung volume, heart rate, 60:77  
lung volume, lactate infusion, 60:77  
respiration, heart rate, 60:77  
respiration, lactate infusion, 60:77

**Borna Disease Virus.** *See* Immunology

**Brain tumor**

affective psychosis, neurologic signs, 58:177  
meningiomas, neurologic signs, 58:177  
meningiomas, psychiatric disturbance, 58:177  
neurologic signs, peritumoral edema, 58:177  
peritumoral edema, affective psychosis, 58:177  
peritumoral edema, neurologic signs, 58:177  
peritumoral edema, psychiatric disturbance, 58:177  
psychiatric disturbance, meningiomas, 58:177  
psychiatric disturbance, peritumoral edema, 58:177

**Brofarnamine**

affective disorder, response prediction, vs. imipramine, 58:107  
late-life depression, response prediction vs. imipramine, 58:107  
therapeutic outcome, early response as a predictor, 58:107

**Bufotenin**

personality, serotonin, violence, 58:145  
serotonin, personality, violence, 58:145  
violence, serotonin, personality, 58:145

**Bulimia nervosa.** *See* Eating disorder

**Calbindin**

frontal lobe,  $\gamma$ -aminobutyric acid, local circuit neurons, 59:81  
frontal lobe, schizophrenia, post-mortem study, 59:81  
 $\gamma$ -aminobutyric acid, frontal lobe, 59:81  
 $\gamma$ -aminobutyric acid, local circuit neurons, schizophrenia, 59:81  
schizophrenia, frontal lobe, post-mortem study, 59:81  
schizophrenia,  $\gamma$ -aminobutyric acid, local circuit neurons, 59:81

**Calcium**

alcohol dependence, serotonin, 57:275  
serotonin, alcohol dependence, 57:275

**Calretinin**

frontal lobe,  $\gamma$ -aminobutyric acid, local circuit neurons, 59:81  
frontal lobe, schizophrenia, post-mortem study, 59:81  
 $\gamma$ -aminobutyric acid, frontal lobe, local circuit neurons, 59:81  
schizophrenia, frontal lobe, post-mortem study, 59:81  
schizophrenia,  $\gamma$ -aminobutyric acid, local circuit neurons, 59:81

**Carbohydrate craving**

affective disorder, circannual rhythm, light therapy, 59:171  
circannual rhythm, seasonal affective disorder, 59:171  
circannual rhythm, taste detection, 59:171  
light therapy, seasonal affective disorder, 59:171  
seasonal affective disorder, light therapy, 59:171  
seasonal affective disorder, taste detection, 59:171  
taste detection, seasonal affective disorder, 59:171



**Carbon dioxide**

- agoraphobia, anxiety disorder, panic attacks, 57:267
- anxiety disorder, agoraphobia, panic attacks, 57:267
- panic attacks, agoraphobia, 57:267

**Child abuse**

- adult survivors, Early Trauma Inventory, 59:97
- adult survivors, memory, 59:97
- Early Trauma Inventory, neuropsychology, 59:97
- memory, Early Trauma Inventory, 59:97
- neuropsychology, adult survivors, 59:97

**Child psychiatry. See Attention deficit hyperactivity disorder; Autism; Conduct disorder; Obsessive-compulsive disorder****Cholecystokinin-8**

- amineptine, anorexia, 59:43
- amineptine, bulimia, 59:51
- anorexia, amineptine, 59:43
- anorexia, fluoxetine, 59:43
- anorexia, T-lymphocytes, 59:43
- bulimia, amineptine, 59:51
- bulimia, fluvoxamine, 59:51
- bulimia, T-lymphocytes, 59:51
- eating disorder, amineptine, 59:43, 59:51
- eating disorder, fluoxetine, 59:43
- eating disorder, fluvoxamine, 59:51
- eating disorder, T-lymphocytes, 59:43, 59:51
- fluoxetine, anorexia, 59:43
- fluvoxamine, bulimia, 59:51
- T-lymphocytes, eating disorder, 59:43, 59:51

**Cholinesterase, serum**

- anxiety, fluvoxamine, 58:265
- anxiety, obsessive-compulsive disorder, 58:265
- fluvoxamine, anxiety, 58:265
- fluvoxamine, obsessive-compulsive disorder, 58:265
- obsessive-compulsive disorder, anxiety, 58:265
- obsessive-compulsive disorder, fluvoxamine, 58:265

**Circadian rhythm**

- Abnormal Involuntary Movements Scale, haloperidol, 56:53
- Abnormal Involuntary Movements Scale, schizophrenia, 56:53
- Abnormal Involuntary Movements Scale, tardive dyskinesia, 56:53
- affective disorder, Arden ratio, 57:197
- affective disorder, circannual rhythm, 56:221, 60:199
- affective disorder, electrooculography, 57:197
- affective disorder, light therapy, 56:221
- affective disorder, melatonin, 56:221
- affective disorder, photoperiod, 60:199
- affective disorder, sleep, deprivation, 57:197
- affective disorder, violence, 60:199
- affective disorder, visual adaptation, 57:197
- Alaska, circannual rhythm, 57:251

- Alaska, nurses' medication errors, 57:251
- animal model, hamster, effects of carbamazepine, lithium, valproate, verapamil, 57:215
- blood pressure, body temperature, heart rate, 57:21
- blood pressure, norepinephrine, 57:21
- blood pressure, schizophrenia, 57:21
- body temperature, blood pressure, heart rate, 57:21
- body temperature, schizophrenia, 57:21
- carbamazepine, animal model, hamster, 57:215
- cortisol, schizophrenia, 57:21
- electrooculography, affective disorder, 57:197
- electrooculography, Arden ratio, 57:197
- electrooculography, sleep, sleep deprivation, 57:197
- electrooculography, visual adaptation, 57:197
- haloperidol, Abnormal Involuntary Movements Scale, 56:53
- haloperidol, schizophrenia, 56:53
- haloperidol, tardive dyskinesia, 56:53
- hamster, animal model, effects of carbamazepine, lithium, valproate, verapamil, 57:215
- heart rate, blood pressure, body temperature, 57:21
- heart rate, schizophrenia, 57:21
- light therapy, affective disorder, 56:221
- light therapy, circannual rhythm, 56:221
- light therapy, melatonin, 56:221
- light therapy, seasonal affective disorder, 56:221
- lithium, animal model, hamster, 57:215
- melatonin, affective disorder, 56:221
- melatonin, circannual rhythm, 56:221
- melatonin, light therapy, 56:221
- melatonin, seasonal affective disorder, 56:221
- norepinephrine, blood pressure, 57:21
- norepinephrine, schizophrenia, 57:21
- photoperiod, affective disorder, 60:199
- photoperiod, circannual rhythm, 60:199
- photoperiod, violence, 60:199
- schizophrenia, Abnormal Involuntary Movements Scale, 56:53
- schizophrenia, blood pressure, 57:21
- schizophrenia, body temperature, 57:21
- schizophrenia, cortisol, 57:21
- schizophrenia, haloperidol, 56:53
- schizophrenia, heart rate, 57:21
- schizophrenia, norepinephrine, 57:21
- schizophrenia, photoperiod, 60:199
- schizophrenia, tardive dyskinesia, 56:53
- schizophrenia, thyroid hormones, 57:21
- seasonal affective disorder, light therapy, 56:221
- seasonal affective disorder, melatonin, 56:221
- sleep, affective disorder, 57:197
- sleep deprivation, affective disorder, 57:197
- sleep, electrooculography, 57:197
- tardive dyskinesia, Abnormal Involuntary Movements Scale, 56:53
- tardive dyskinesia, haloperidol, 56:53
- tardive dyskinesia, schizophrenia, 56:53
- thyroid hormones, schizophrenia, 57:21
- valproate, animal model, hamster, 57:215

verapamil, animal model, hamster, 57:215  
 violence, photoperiod, 60:199  
 visual adaptation, affective disorder, 57:197  
 visual adaptation, Arden ratio, 57:197  
 visual adaptation, electrooculography, 57:197  
 work performance, Alaska, 57:251  
 work performance, nurses' medication errors, 57:251

### Circannual rhythm

affective disorder, carbohydrate craving, 59:171  
 affective disorder, circadian rhythm, 56:221, 60:199  
 affective disorder, electrooculographic ratio, 59:151  
 affective disorder, ethology, 57:223  
 affective disorder, light therapy, 56:11, 56:221, 57:223, 59:171  
 affective disorder, melatonin, 56:221  
 affective disorder, photoperiod, 60:199  
 affective disorder, retina, 59:151  
 affective disorder, taste detection, 59:171  
 carbohydrate craving, affective disorder, 59:171  
 carbohydrate craving, light therapy, 59:171  
 carbohydrate craving, seasonal affective disorder, 59:171  
 carbohydrate craving, taste detection, 59:171  
 electrooculographic ratio, affective disorder, 59:151  
 electrooculographic ratio, retina, 59:151  
 electrooculographic ratio, seasonal affective disorder, 59:151  
 ethology, affective disorder, 57:223  
 ethology, light therapy, 57:223  
 ethology, seasonal affective disorder, 57:223  
 light therapy, carbohydrate craving, 59:171  
 light therapy, ethology, 57:223  
 light therapy, melatonin, 56:221  
 light therapy, seasonal affective disorder, 56:11, 56:221, 57:223, 59:171  
 light therapy, Southern Hemisphere, 56:11  
 light therapy, taste detection, 59:171  
 melatonin, affective disorder, 56:221  
 melatonin, light therapy, 56:221  
 melatonin, seasonal affective disorder, 56:221  
 photoperiod, affective disorder, 60:199  
 photoperiod, circadian rhythm, 60:199  
 photoperiod, schizophrenia, 60:199  
 photoperiod, violence, 60:199  
 retina, affective disorder, 59:151  
 retina, electrooculographic ratio, 59:151  
 retina, seasonal affective disorder, 59:151  
 schizophrenia, photoperiod, 60:199  
 seasonal affective disorder, carbohydrate craving, 59:171  
 seasonal affective disorder, electrooculographic ratio, 59:151  
 seasonal affective disorder, ethology, 57:223  
 seasonal affective disorder, light therapy, 56:11, 56:221, 57:223, 59:171  
 seasonal affective disorder, melatonin, 56:221  
 seasonal affective disorder, retina, 59:151  
 seasonal affective disorder, Southern Hemisphere, 56:11  
 seasonal affective disorder, taste detection, 59:171  
 taste detection, affective disorder, 59:171

taste detection, carbohydrate craving, 59:171  
 taste detection, light therapy, 59:171  
 taste detection, seasonal affective disorder, 59:171  
 violence, photoperiod, 60:199  
 work performance, Alaska, 57:251  
 work performance, nurses' medication errors, 57:251

### Clonidine

affective disorder, cortisol, dexamethasone, 60:23  
 affective disorder, growth hormone, 60:23  
 cortisol, dexamethasone, affective disorder, 60:23  
 dexamethasone, cortisol, affective disorder, 60:23  
 growth hormone, affective disorder, 60:23

### Cognition. *See also* Attention; Neuropsychology

Allen Cognitive Levels, cross-cultural comparison, African-American, Mexican-American, 56:101  
 Mexican-American, 56:101  
 Allen Cognitive Levels, schizoaffective disorder, schizophrenia, 56:101  
 Alzheimer's Disease, deprenyl effects, 58:181  
 Alzheimer's Disease, monoamine oxidase inhibitor, 58:181  
 Alzheimer's Disease, physostigmine, 58:181  
 backward masking, personality disorder, 60:49  
 backward masking, schizophrenia, schizotypal personality, 60:49  
 Continuous Performance Test, personality disorder, 60:49  
 Continuous Performance Test, schizophrenia, schizotypal personality, 60:49  
 cross-cultural, African-American, Mexican-American, 56:101  
 cross-cultural, schizoaffective disorder, schizophrenia, 56:101  
 dementia, deprenyl, 58:181  
 dementia, monoamine oxidase inhibitor, 58:181  
 dementia, physostigmine, 58:181  
 deprenyl, Alzheimer's Disease, 58:181  
 deprenyl, dementia, 58:181  
 monoamine oxidase inhibitor, Alzheimer's Disease, 58:181  
 monoamine oxidase inhibitor, dementia, 58:181  
 memory, schizoaffective disorder, schizophrenia, 57:141  
 memory, sex difference, 57:141  
 memory, social skill, 57:141  
 personality disorder, backward masking, 60:49  
 personality disorder, Continuous Performance Test, 60:49  
 physostigmine, Alzheimer's Disease, 58:181  
 physostigmine, dementia, 58:181  
 schizoaffective disorder, Allen Cognitive Levels, 56:101  
 schizoaffective disorder, cross-cultural, 56:101  
 schizoaffective disorder, memory, 57:141  
 schizoaffective disorder, sex difference, 57:141  
 schizoaffective disorder, social skill, 57:141  
 schizophrenia, Allen Cognitive Levels, 56:101  
 schizophrenia, backward masking, 60:49  
 schizophrenia, Continuous Performance Test, 60:49  
 schizophrenia, cross-cultural, 56:101  
 schizophrenia, memory, 57:141



schizophrenia, sex difference, 57:141  
 schizophrenia, social skill, 57:141  
 schizotypal personality, backward masking, 60:49  
 schizotypal personality, Continuous Performance Test, 60:49  
 sex, memory, 57:141  
 sex, schizoaffective disorder, schizophrenia, 57:141  
 sex, social skill, 57:141  
 social skill, memory, 57:141  
 social skill, schizoaffective disorder, 57:141  
 social skill, sex, 57:141

#### **Conduct disorder**

aggression, genetics, 59:35  
 dinucleotide repeat polymorphism, monoamine oxidase type A gene, 59:35  
 genetics, polymerase chain reaction, 59:35  
 monoamine oxidase type A gene, 59:35

#### **Cortisol**

abstinence, alcohol dependence, 56:81  
 affective disorder, clonidine, 60:23  
 affective disorder, computed tomography, 59:157  
 affective disorder, desipramine, 60:191  
 affective disorder, dexamethasone, 60:23  
 alcohol dependence, abstinence, 56:81  
 atypical depression, desipramine, 60:191  
 autism, naltrexone, 58:203  
 circadian rhythm, schizophrenia, 57:21  
 computed tomography, affective disorder, 59:157  
 desipramine, affective disorder, 60:191  
 desipramine, atypical depression, 60:191  
 dexamethasone, affective disorder, 60:23  
 dexamethasone, metyrapone, 58:23  
 heroin, substance dependence, 58:153  
 impulsivity, personality, 60:177  
 meta-chlorophenylpiperazine, pindolol, 58:89  
 metyrapone, dexamethasone, 58:23  
 naltrexone, autism, 58:203  
 naltrexone,  $\beta$ -endorphin, 58:203  
 naltrexone, social behavior, 58:203  
 pindolol, meta-chlorophenylpiperazine, 58:89  
 schizophrenia, circadian rhythm, 57:21

#### **Computed tomography**

personality disorder, ventricle-brain ratio, 57:109  
 schizophrenia, ventricle-brain ratio, 57:109, 60:125  
 schizotypal personality disorder, ventricle-brain ratio, 57:109  
 ventricle-brain ratio, personality disorder, 57:109  
 ventricle-brain ratio, schizophrenia, 57:109, 60:125  
 ventricle-brain ratio, schizotypal personality disorder, 57:109

#### **Cost-benefit analysis**

bulimia, cognitive-behavioral therapy, desipramine, 58:13  
 cognitive-behavioral therapy, desipramine, bulimia, 58:13  
 desipramine, cognitive-behavioral therapy, bulimia, 58:13

#### **Cross-cultural**

African-American, Allen Cognitive Levels, 56:101

African-American, schizoaffective disorder, schizophrenia, 56:101  
 Allen Cognitive Levels, African-American, Mexican-American, 56:101  
 Allen Cognitive Levels, schizoaffective disorder, schizophrenia, 56:101  
 Center for Epidemiologic Studies Depression Scale, Japan vs. U.S., 58:237  
 cognition, African-American, Mexican-American, 56:101  
 cognition, schizoaffective disorder, schizophrenia, 56:101  
 depression, epidemiology, Japan vs. U.S., 58:237  
 epidemiology, depression, Japan vs. U.S., 58:237  
 Mexican-American, Allen Cognitive Levels, 56:101  
 Mexican-American, schizoaffective disorder, schizophrenia, 56:101  
 schizoaffective disorder, African-American, Mexican-American, 56:101  
 schizoaffective disorder, Allen Cognitive Levels, 56:101  
 schizophrenia, African-American, Mexican-American, 56:101  
 schizophrenia, Allen Cognitive Levels, 56:101

#### **Dementia. See also Alzheimer's Disease**

age, brain volume, 57:119  
 age, magnetic resonance imaging, 57:119  
 age, sex, 57:119  
 age, temporal lobe, 57:119  
 agitation, light therapy, 57:7  
 agitation, sundowning, 57:7  
 anticardiolipin antibody, immunology, 58:83  
 anticardiolipin antibody, vascular signs, 58:83  
 autoantibody reactivity, immunology, 59:251  
 brain volume, age, 57:119  
 brain volume, discriminant analysis, 57:119  
 brain volume, magnetic resonance imaging, 57:119  
 brain volume, sex, 57:119  
 brain volume, temporal lobe, 57:119  
 cognition, deprenyl, 58:181  
 cognition, monoamine oxidase inhibitor, 58:181  
 cognition, physostigmine, 58:181  
 deprenyl, cognition, 58:181  
 distractibility, age, 57:119  
 distractibility, brain volume, 57:119  
 distractibility, magnetic resonance imaging, 57:119  
 distractibility, sex, 57:119  
 distractibility, temporal lobe, 57:119  
 evoked potentials, genetics, 57:57  
 evoked potentials, oddball paradigm, 57:57  
 evoked potentials, risk study, 57:57  
 genetics, evoked potentials, 57:57  
 genetics, risk study, 57:57  
 immunology, anticardiolipin antibody, 58:83  
 immunology, autoantibody reactivity, 59:251  
 immunology, vascular signs, 58:83  
 light therapy, agitation, 57:7  
 light therapy, sundowning, 57:7  
 magnetic resonance imaging, age, 57:119  
 magnetic resonance imaging, brain volume, 57:119

magnetic resonance imaging, discriminant analysis, 57:119  
 magnetic resonance imaging, sex, 57:119  
 magnetic resonance imaging, temporal lobe, 57:119  
 monoamine oxidase inhibitor, cognition, 58:181  
 pharmacokinetics, serotonin, 59:145  
 physostigmine, cognition, 58:181  
 serotonin, pharmacokinetics, 59:145  
 sex, age, 57:119  
 sex, brain volume, 57:119  
 sex, magnetic resonance imaging, 57:119  
 sex, temporal lobe, 57:119  
 sundowning, agitation, 57:7  
 sundowning, light therapy, 57:7  
 temporal lobe, age, 57:119  
 temporal lobe, magnetic resonance imaging, 57:119  
 temporal lobe, sex, 57:119  
 vascular signs, anticardiolipin antibody, 58:83  
 vascular signs, immunology, 58:83

### 2-Deoxyglucose

amphetamine, rat, 57:65  
 local cerebral glucose, amphetamine, 57:65  
 local cerebral glucose, rat, 57:65

### Deprenyl

Alzheimer's Disease, cognition, 58:181  
 cognition, Alzheimer's Disease, dementia, 58:181  
 monoamine oxidase inhibitor, dementia, 58:181

### Depressed mood

human immunodeficiency virus, intake interview, 59:245  
 human immunodeficiency virus, Structured Clinical Interview for DSM-III-R, 59:245  
 human immunodeficiency virus, visual analogue scale, 59:245  
 intake interview, Structured Clinical Interview for DSM-III-R, 59:245  
 Structured Clinical Interview for DSM-III-R, human immunodeficiency virus, 59:245  
 visual analogue scale, human immunodeficiency virus, 59:245

### Dexamethasone

affective disorder, cortisol, 60:23  
 cortisol, affective disorder, 60:23  
 cortisol, metyrapone, 58:23  
 metyrapone, cortisol, 58:23  
 Dinucleotide repeat polymorphism  
 aggression, conduct disorder, genetics, 59:35  
 aggression, monoamine oxidase type A gene, 59:35  
 conduct disorder, genetics, 59:35  
 conduct disorder, monoamine oxidase type A gene, 59:35  
 genetics, aggression, conduct disorder, 59:35  
 genetics, polymerase chain reaction, 59:35  
 monoamine oxidase type A gene, aggression, conduct disorder, 59:35

### Dopamine

animal model, rat, apomorphine, 58:165

apomorphine, animal model, rat, 58:165  
 French population, genetics, linkage analysis, schizophrenia, 59:1  
 genetics, linkage analysis, schizophrenia, 59:1  
 homovanillic acid, prolactin, 58:23  
 linkage analysis, genetics, schizophrenia, 59:1  
 prolactin, homovanillic acid, 58:23  
 rat, animal model, apomorphine, 58:165  
 schizophrenia, French population, genetics, linkage analysis, 59:1

### Dopamine- $\beta$ -hydroxylase

affective disorder, bipolar subtype, 59:165  
 affective disorder, lithium, 59:165  
 bipolar affective disorder, lithium, 59:165  
 lithium, affective disorder, bipolar subtype, 59:165

### Eating disorder

aggression, anorexia, bulimia, 56:205  
 amineptine, anorexia, 59:43  
 amineptine,  $\beta$ -endorphin, 59:43, 59:51  
 amineptine, bulimia, 59:51  
 amineptine, cholecystokinin-8, 59:43, cholecystokinin-8, 59:51  
 anger attacks, anorexia, bulimia, 56:205  
 anorexia, aggression, 56:205  
 anorexia, amineptine, 59:43  
 anorexia, anger attacks, 56:205  
 anorexia,  $\beta$ -endorphin, 59:43  
 anorexia, cholecystokinin-8, 59:43  
 anorexia, cholesterol, 59:255  
 anorexia, erythrocyte membrane, 59:255  
 anorexia, fluoxetine, 59:43  
 anorexia, lipids, 59:255  
 anorexia, peptides, 59:43  
 anorexia, refeeding, 59:255  
 anorexia, T-lymphocytes, 59:43  
 $\beta$ -endorphin, amineptine, 59:43, 59:51  
 $\beta$ -endorphin, anorexia, 59:43  
 $\beta$ -endorphin, bulimia, 59:51  
 $\beta$ -endorphin, cholecystokinin-8, 59:43, 59:51  
 $\beta$ -endorphin, fluoxetine, 59:43  
 $\beta$ -endorphin, fluvoxamine, 59:51  
 $\beta$ -endorphin, T-lymphocytes, 59:43, 59:51  
 bulimia, aggression, 56:205  
 bulimia, amineptine, 59:51  
 bulimia, anger attacks, 56:205  
 bulimia,  $\beta$ -endorphin, 59:51  
 bulimia, cholecystokinin-8, 59:51  
 bulimia, cognitive-behavioral therapy, 58:13  
 bulimia, cost-benefit analysis, 58:13  
 bulimia, depression, 60:1  
 bulimia, desipramine, 58:13  
 bulimia, fluvoxamine, 59:51  
 bulimia, light therapy, 60:1  
 bulimia, T-lymphocytes, 59:51  
 bulimia, peptides, 59:51

cholecystokinin-8, amineptine, 59:43, 59:51  
 cholecystokinin-8, anorexia, 59:43  
 cholecystokinin-8,  $\beta$ -endorphin, 59:43, 59:51  
 cholecystokinin-8, bulimia, 59:51  
 cholecystokinin-8, fluoxetine, 59:43  
 cholecystokinin-8, fluvoxamine, 59:51  
 cholecystokinin-8, T-lymphocytes, 59:43, 59:51  
 cholesterol, anorexia, 59:255  
 cholesterol, erythrocyte membrane, 59:255  
 cholesterol, lipids, 59:255  
 cholesterol, refeeding, 59:255  
 cognitive-behavioral therapy, bulimia, 58:13  
 cognitive-behavioral therapy, cost-benefit analysis, 58:13  
 cognitive-behavioral therapy, desipramine, 58:13  
 cost-benefit analysis, bulimia, 58:13  
 cost-benefit analysis, cognitive-behavioral therapy, 58:13  
 cost-benefit analysis, desipramine, 58:13  
 depression, bulimia, 60:1  
 desipramine, bulimia, 58:13  
 desipramine, cognitive-behavioral therapy, 58:13  
 desipramine, cost-benefit analysis, 58:13  
 erythrocyte membrane, anorexia, 59:255  
 erythrocyte membrane, cholesterol, 59:255  
 erythrocyte membrane, lipids, 59:255  
 fluoxetine, amineptine, 59:43  
 fluoxetine, anorexia, 59:43  
 fluoxetine,  $\beta$ -endorphin, 59:43  
 fluoxetine, cholecystokinin-8, 59:43  
 fluoxetine, peptides, 59:43  
 fluvoxamine, amineptine, 59:51  
 fluvoxamine,  $\beta$ -endorphin, 59:51  
 fluvoxamine, bulimia, 59:51  
 fluvoxamine, cholecystokinin-8, 59:51  
 fluvoxamine, peptides, 59:51  
 light therapy, bulimia, 60:1  
 lipids, anorexia, 59:255  
 lipids, cholesterol, 59:255  
 lipids, erythrocyte membrane, 59:255  
 lipids, refeeding, 59:255  
 peptides, anorexia, 59:43  
 peptides, bulimia, 59:51  
 refeeding, anorexia, 59:255  
 T-lymphocytes,  $\beta$ -endorphin, 59:43, 59:51  
 T-lymphocytes, bulimia, 59:51  
 T-lymphocytes, cholecystokinin-8, 59:43

#### **Electroconvulsive therapy**

affective disorder, ondansetron, prolactin, serotonin, 60:33  
 ondansetron, affective disorder, prolactin, serotonin, 60:33  
 prolactin, ondansetron, serotonin, affective disorder, 60:33  
 serotonin, prolactin, ondansetron, affective disorder, 60:33

#### **Electroencephalography. See also Evoked potentials; Polysomnography**

alcohol, substance dependence, 58:247  
 cocaine, marijuana, 58:247  
 marijuana, alcohol, cocaine, 58:247  
 substance dependence, 58:247

#### **Electrooculography**

affective disorder, Arden ratio, 57:197  
 affective disorder, circadian rhythm, 57:197  
 affective disorder, circannual rhythm, 59:151  
 affective disorder, retina, 59:151  
 affective disorder, visual adaptation, 57:197  
 Arden ratio, affective disorder, 57:197  
 Arden ratio, circadian rhythm, 57:197  
 Arden ratio, visual adaptation, 57:197  
 attention, schizophrenia, 59:221  
 attention, smooth pursuit eye movements, 59:221  
 attention, tardive dyskinesia, 59:221  
 caudate nucleus, eye movements, 58:53  
 caudate nucleus, frontal eye fields, 58:53  
 caudate nucleus, positron emission tomography, 58:53  
 caudate nucleus, schizophrenia, 58:53  
 caudate nucleus, smooth pursuit eye movements, 58:53  
 circadian rhythm, affective disorder, 57:197  
 circadian rhythm, Arden ratio, 57:197  
 circadian rhythm, visual adaptation, 57:197  
 circannual rhythm, affective disorder, 59:151  
 circannual rhythm, retina, 59:151  
 circannual rhythm, seasonal affective disorder, 59:151  
 eye movements, caudate nucleus, 58:53  
 eye movements, frontal eye fields, 58:53  
 eye movements, positron emission tomography, 58:53  
 eye movements, schizophrenia, 58:53  
 eye movements, smooth pursuit, 58:53  
 frontal eye fields, caudate nucleus, 58:53  
 frontal eye fields, eye movements, 58:53  
 frontal eye fields, positron emission tomography, 58:53  
 frontal eye fields, schizophrenia, 58:53  
 frontal eye fields, smooth pursuit tracking, 58:53  
 positron emission tomography, caudate nucleus, 58:53  
 positron emission tomography, frontal eye fields, 58:53  
 positron emission tomography, schizophrenia, 58:53  
 positron emission tomography, smooth pursuit eye movements, 58:53  
 retina, affective disorder, 59:151  
 retina, circannual rhythm, 59:151  
 retina, seasonal affective disorder, 59:151  
 schizophrenia, attention, 59:221  
 schizophrenia, caudate nucleus, 58:53  
 schizophrenia, eye movements, 58:53  
 schizophrenia, frontal eye fields, 58:53  
 schizophrenia, positron emission tomography, 58:53  
 schizophrenia, smooth pursuit eye tracking, 58:53, 59:221  
 schizophrenia, tardive dyskinesia, 59:221  
 seasonal affective disorder, circannual rhythm, 59:151  
 seasonal affective disorder, retina, 59:151  
 smooth pursuit eye tracking, attention, 59:221  
 smooth pursuit eye tracking, caudate nucleus, 58:53  
 smooth pursuit eye tracking, positron emission tomography, 58:53  
 smooth pursuit eye tracking, schizophrenia, 58:53, 59:221  
 smooth pursuit eye tracking, tardive dyskinesia, 59:221  
 tardive dyskinesia, attention, 59:221

tardive dyskinesia, schizophrenia, 59:221  
 tardive dyskinesia, smooth pursuit eye tracking, 59:221  
 visual adaptation, affective disorder, 57:197  
 visual adaptation, Arden ratio, 57:197  
 visual adaptation, circadian rhythm, 57:197

### **Epidemiology**

affective disorder, anxiety disorder, 57:169, 58:1, 59:57  
 affective disorder, bipolar subtype, 59:57  
 affective disorder, Family History Screen for Epidemiologic Studies, 57:169  
 affective disorder, genetics, 57:169  
 affective disorder, obsessive-compulsive disorder, 59:57  
 affective disorder, panic disorder, 59:57  
 affective disorder, sex, 58:1  
 affective disorder, substance abuse, 57:169  
 affective disorder, suicidality, 59:57  
 affective disorder, unipolar subtype, 59:57  
 anxiety disorder, affective disorder, 57:169, 58:1, 59:57  
 anxiety disorder, Family History Screen for Epidemiologic Studies, 57:169  
 anxiety disorder, genetics, 57:169  
 anxiety disorder, obsessive-compulsive disorder, 59:57  
 anxiety disorder, sex, 58:1  
 anxiety disorder, substance abuse, 57:169  
 bipolar affective disorder, suicidality, 59:57  
 Center for Epidemiologic Studies Depression Scale, cross-cultural, 58:237  
 Center for Epidemiologic Studies Depression Scale, Japan vs. U.S., 58:237  
 comorbidity, 59:57  
 cross-cultural, Center for Epidemiologic Studies Depression Scale, 58:237  
 cross-cultural, Japan vs. U.S., 58:237  
 depression, cross-cultural, Japan vs. U.S., 58:237  
 Family History Screen for Epidemiologic Studies, genetics, 57:169  
 genetics, affective disorder, anxiety disorder, substance abuse, 57:169  
 obsessive-compulsive disorder, affective disorder, 59:57  
 obsessive-compulsive disorder, anxiety disorder, 59:57  
 obsessive-compulsive disorder, panic disorder, 59:57  
 panic disorder, affective disorder, 59:57  
 panic disorder, obsessive-compulsive disorder, 59:57  
 schizophrenia, season of birth, 60:205  
 schizophrenia, Southern Hemisphere, 60:205  
 season of birth, schizophrenia, 60:205  
 season of birth, Southern Hemisphere, 60:205  
 sex, affective disorder, 58:1  
 sex, anxiety disorder, 58:1  
 substance abuse, affective disorder, 57:169  
 substance abuse, anxiety disorder, 57:169  
 substance abuse, Family History Screen for Epidemiologic Studies, 57:169  
 substance abuse, genetics, 57:169  
 suicidality, bipolar affective disorder, 59:57  
 unipolar depression, anxiety disorder, 59:57  
 unipolar depression, suicidality, 59:57

### **Ethology**

circannual rhythm, seasonal affective disorder, light therapy, 57:223  
 light therapy, seasonal affective disorder, circannual rhythm, 57:223  
 seasonal affective disorder, light therapy, circannual rhythm, 57:223

### **Evoked potentials**

Alzheimer's Disease, risk study, 57:57  
 attention, P300 component, oddball paradigm, 58:69  
 attention, reaction time, schizophrenia, 58:69  
 dementia, risk study, 57:57  
 gating, mismatch detection, 57:83  
 gating, P50 component, 56:271, 57:83  
 gating, rapid eye movement sleep, 56:271  
 gating, schizophrenia, 56:271  
 gating, slow wave sleep, 56:271  
 genetics, Alzheimer's Disease, 57:57  
 genetics, dementia, 57:57  
 genetics, risk study, 57:57  
 mismatch detection, gating, P50 component, 57:83  
 neuroleptic effects, late component, 56:229  
 neuroleptic effects, schizophrenia, 56:229  
 reaction time, attention, P300 component, schizophrenia, 58:69  
 rapid eye movement sleep, gating, P50 component, schizophrenia, 56:271  
 schizophrenia, attention, 58:69  
 schizophrenia, gating, 56:271  
 schizophrenia, neuroleptic effects on late component, 56:229  
 schizophrenia, oddball paradigm, 56:237  
 schizophrenia, P300 component, 58:69  
 schizophrenia, P50 component, 56:271  
 schizophrenia, reaction time, 58:69  
 schizophrenia, rapid eye movement sleep, 56:271  
 schizophrenia, slow wave sleep, 56:271  
 schizophrenia, variability, 56:237  
 sleep, gating, P50 component, 56:271  
 sleep, rapid eye movement, 56:271  
 sleep, schizophrenia, 56:271  
 sleep, slow wave, 56:271  
 slow wave sleep, gating, P50 component, schizophrenia, 56:271  
 variability, oddball paradigm, schizophrenia, 56:237

### **Expressed emotion**

affective disorder, bipolar subtype, 56:299  
 affective disorder, family therapy, psychoeducation, 56:299  
 bipolar affective disorder, family therapy, psychoeducation, 56:299  
 communication deviance, family interactions, 56:121  
 communication deviance, prognosis, 56:121  
 communication deviance, schizoaffective disorder, schizophrenia, 56:121  
 communication deviance, social skills, 56:121  
 content analysis, family environment, 57:155  
 content analysis, speech, 57:155  
 family environment, content analysis, 57:155  
 family environment, schizophrenia, 57:155

family environment, speech, 57:155  
 family interactions, communication deviance, 56:121  
 family interactions, prognosis, 56:121  
 family interactions, schizoaffective disorder, schizophrenia, 56:121  
 family interactions, social skills, 56:121  
 family therapy, affective disorder, bipolar subtype, 56:299  
 family therapy, psychoeducation, 56:299  
 prognosis, communication deviance, family interactions, 56:121  
 prognosis, schizoaffective disorder, schizophrenia, 56:121  
 prognosis, social skills, 56:121  
 psychoeducation, affective disorder, bipolar subtype, 56:299  
 psychoeducation, family therapy, 56:299  
 schizoaffective disorder, communication deviance, 56:121  
 schizoaffective disorder, family interactions, 56:121  
 schizoaffective disorder, prognosis, 56:121  
 schizoaffective disorder, social skills, 56:121  
 schizophrenia, communication deviance, 56:121  
 schizophrenia, family environment, 57:155  
 schizophrenia, family interactions, 56:121  
 schizophrenia, prognosis, 56:121  
 schizophrenia, social skills, 56:121  
 social skills, communication deviance, 56:121  
 social skills, family interactions, 56:121  
 social skills, schizoaffective disorder, schizophrenia, 56:121  
 speech, content analysis, family environment, 57:155

# **Fenfluramine**

cortisol, depression, 58:153  
 cortisol, heroin abuse, 58:153  
 heroin abuse, comorbid depression, 58:153  
 heroin abuse, cortisol, 58:153  
 heroin abuse, prolactin, 58:153  
 prolactin, depression, 58:153  
 prolactin, heroin abuse, 58:153

# **Gamma-aminobutyric acid**

alcohol dependence, levels during abstinence and withdrawal, 59:137  
 alcohol dependence, liver function, 59:137  
 anxiety, liver function, 59:137  
 baclofen, growth hormone, 60:41  
 calbindin, frontal lobe, local circuit neurons, 59:81  
 calbindin, post-mortem study, schizophrenia, 59:81  
 calretinin, frontal lobe, local circuit neurons, 59:81  
 calretinin, post-mortem study, schizophrenia, 59:81  
 frontal lobe, calbindin, calretinin, local circuit neurons, 59:81  
 liver function, alcohol dependence, 59:137  
 liver function, anxiety, 59:137  
 local circuit neurons in the frontal lobe, calbindin, calretinin, 59:81  
 local circuit neurons, schizophrenia, post-mortem study, 59:81  
 schizophrenia, calbindin, calretinin, 59:81  
 schizophrenia, frontal lobe, local circuit neurons, post-mortem study, 59:81

# **Genetics**

affective disorder, bipolar subtype, 59:7  
 affective disorder, chromosome 18, 59:7  
 affective disorder, Family History Screen for Epidemiologic Studies, 57:169  
 affective disorder, linkage analysis, 59:7  
 age of onset, anticipation, schizophrenia, 59:25  
 aggression, conduct disorder, 59:35  
 aggression, dinucleotide repeat polymorphism, 59:35  
 aggression, monoamine oxidase type A gene, 59:35  
 anxiety disorder, Family History Screen for Epidemiologic Studies, 57:169  
 attention deficit hyperactivity disorder, serotonin, 57:13  
 bipolar subtype, affective disorder, 59:7  
 bipolar subtype, chromosome 18, 59:7  
 bipolar subtype, linkage analysis, 59:7  
 catatonic subtype, pseudoautosomal inheritance, 59:17  
 catatonic subtype, schizophrenia, 59:17  
 catatonic subtype, sex concordance, 59:17  
 chromosome 18, bipolar affective disorder, 59:7  
 chromosome 18, linkage analysis, 59:7  
 conduct disorder, dinucleotide repeat polymorphism, 59:35  
 conduct disorder, monoamine oxidase type A gene, 59:35  
 dinucleotide repeat polymorphism, aggression, 59:35  
 dinucleotide repeat polymorphism, conduct disorder, 59:35  
 dinucleotide repeat polymorphism, monoamine oxidase type A gene, 59:35  
 dinucleotide repeat polymorphism, personality, 59:35  
 dinucleotide repeat polymorphism, polymerase chain reaction, 59:35  
 dopamine transporter gene, French population, 59:1  
 dopamine transporter gene, linkage analysis, 59:1  
 dopamine transporter gene, schizophrenia, 59:1  
 linkage analysis, affective disorder, bipolar subtype, 59:7  
 linkage analysis, chromosome 18, 59:7  
 linkage analysis, dopamine transporter gene, French population, 59:1  
 linkage analysis, schizophrenia, 59:1  
 monoamine oxidase type A gene, aggression, 59:35  
 monoamine oxidase type A gene, conduct disorder, 59:35  
 monoamine oxidase type A gene, dinucleotide repeat polymorphism, 59:35  
 monoamine oxidase type A gene, personality, 59:35  
 oppositional-defiant disorder, serotonin, 57:13  
 personality, dinucleotide repeat polymorphism, 59:35  
 personality, monoamine oxidase type A gene, 59:35  
 polymerase chain reaction, dinucleotide repeat polymorphism, 59:35  
 pseudoautosomal inheritance, catatonic subtype, 59:17  
 pseudoautosomal inheritance, schizophrenia, 59:17  
 pseudoautosomal inheritance, sex concordance, 59:17  
 schizophrenia, age of onset, 59:25  
 schizophrenia, anticipation, 59:25  
 schizophrenia, catatonic subtype, 59:17  
 schizophrenia, dopamine transporter gene, 59:1  
 schizophrenia, French population, 59:1  
 schizophrenia, linkage analysis, 59:1  
 schizophrenia, pseudoautosomal inheritance, 59:17



schizophrenia, sex concordance, 59:17  
serotonin, attention deficit hyperactivity disorder, 57:13  
serotonin, conduct disorder, 57:13  
serotonin, oppositional-defiant disorder, 57:13  
sex concordance, catatonic subtype, 59:17  
sex concordance, pseudoautosomal inheritance, 59:17  
sex concordance, schizophrenia, 59:17  
substance abuse, Family History Screen for Epidemiologic Studies, 57:169  
substance abuse, twin study, 56:213  
twin study, substance abuse, 56:213

**Geriatric psychiatry. See Affective disorder; Alzheimer's Disease, Dementia; Schizophrenia**

**Growth hormone**

affective disorder, clonidine, 60:23  
baclofen,  $\gamma$ -aminobutyric acid, 60:41  
clonidine, affective disorder, 60:23  
 $\gamma$ -aminobutyric acid, baclofen, 60:41

**Heart rate**

affective disorder, amitriptyline, 56:279  
affective disorder, delirium, 56:279  
amitriptyline, affective disorder, 56:279  
amitriptyline, delirium, 56:279  
anxiety disorder, isoproterenol, 56:289  
anxiety disorder, sympathovagal ratio, 56:289  
circadian rhythm, schizophrenia, 57:21  
delirium, affective disorder, 56:279  
delirium, amitriptyline, 56:279  
isoproterenol, anxiety disorder, 56:289  
isoproterenol, panic disorder, 56:289  
isoproterenol, sympathovagal ratio, 56:289  
lactate infusion, cross-spectral analysis, 60:77  
panic disorder, isoproterenol, 56:289  
panic disorder, sympathovagal ratio, 56:289  
schizoaffective disorder, disorganized symptoms, 57:241  
schizoaffective disorder, negative symptoms, 57:241  
schizoaffective disorder, positive symptoms, 57:241  
schizophrenia, circadian rhythm, 57:21  
schizophrenia, disorganized symptoms, 57:241  
schizophrenia, negative symptoms, 57:241  
schizophrenia, norepinephrine, 57:21  
schizophrenia, positive symptoms, 57:241  
spectral analysis, 56:289, 60:77  
spectral analysis, sympathovagal ratio, 56:289  
sympathovagal ratio, anxiety disorder, 56:289  
sympathovagal ratio, isoproterenol, 56:289  
sympathovagal ratio, panic disorder, 56:289

**Homovanillic acid**

corticosteroid-dopaminergic interaction, 58:23  
dexamethasone vs. metyrapone administration, 58:23

**Human immunodeficiency virus**

anxiety, visual analogue scale, 59:245

depression, Structured Clinical Interview for DSM-III-R at intake, 59:245  
depression, visual analogue scale, 59:245  
Structured Clinical Interview for DSM-III-R at intake, anxiety, depression, 59:245  
visual analogue scale, anxiety, depression, 59:245  
5-Hydroxyindoleacetic acid  
anxiety disorder, serotonin, 57:1  
anxiety disorder, urinary measures, 57:1  
meta-analysis, schizophrenia, 59:239  
meta-analysis, serotonin, 59:239  
schizophrenia, meta-analysis, 59:239  
schizophrenia, serotonin, 59:161, 59:239  
serotonin, anxiety disorder, 57:1  
serotonin, meta-analysis, 59:239  
serotonin, schizophrenia, 59:161, 59:239  
serotonin, violence, 59:161  
statistics, meta-analysis, 59:239  
violence, serotonin, 59:161  
Hypothalamic-pituitary-gonadal axis  
alcohol dependence, abstinence, 56:81  
gonadotropin, schizophrenia, 57:231  
gonadotropin-releasing hormone, schizophrenia, 57:231  
luteinizing hormone, schizophrenia, 57:231  
schizophrenia, gonadotropin, luteinizing hormone, testosterone, 57:231  
testosterone, schizophrenia, 57:231

**Imipramine**

affective disorder, combined treatment with paroxetine, 59:189  
affective disorder, response prediction, 58:107  
affective disorder, treatment outcome vs. monoamine oxidase inhibitor brofaromine, 58:107  
paroxetine effects on metabolism, 59:189  
pharmacokinetics, effect of combined treatment with serotonin reuptake inhibitor, 59:189  
serotonin reuptake inhibitor, effects on tricyclic metabolism, 59:189

**Immunology**

Alzheimer's Disease, autoantibody reactivity, 59:251  
anticardiolipin antibody, dementia, 58:83  
anticardiolipin antibody, vascular signs, 58:83  
autoantibody reactivity, Alzheimer's Disease, 59:251  
autoantibody reactivity, dementia, 59:251  
Borna Disease virus, magnetic resonance imaging, schizophrenia, 56:33  
dementia, anticardiolipin antibody, 58:83  
dementia, autoantibody reactivity, 59:251  
dementia, vascular signs, 58:83  
magnetic resonance imaging, Borna Disease virus, schizophrenia, 56:33  
putamen, Borna Disease virus, 56:33  
schizophrenia, Borna Disease virus, 56:33  
vascular signs, anticardiolipin antibody, 58:83  
vascular signs, dementia, 58:83

**Impulsivity**

- calcium, cortisol, paroxetine, serotonin, 60:177
- cortisol, calcium, paroxetine, cortisol, serotonin, 60:177
- paroxetine, calcium, cortisol, 60:177
- serotonin, calcium, cortisol, 60:177
- Inventory of Complicated Grief
- bereavement, factor analysis, 59:65
- depression, factor analysis, 59:65

**Intelligence**

- genetics, schizophrenia, 56:135
- matching fallacy, schizophrenia, 56:135

**Isoproterenol**

- anxiety disorder, heart rate, sympathovagal ratio, 56:289
- heart rate, anxiety-panic disorder, 56:289
- heart rate, spectral analysis, 56:289
- panic disorder, heart rate, sympathovagal ratio, 56:289
- spectral analysis, heart rate, 56:289
- sympathovagal ratio, anxiety-panic disorder, 56:289

**Ketone reductase**

- haloperidol, reduced haloperidol, schizophrenia, 57:101
- schizophrenia, haloperidol, reduced haloperidol, 57:101

**Laterality**

- affective disorder, anhedonia, 56:163
- affective disorder, bipolar subtype, 56:163, 57:279
- affective disorder, motor activity, 57:279
- affective disorder, skin conductance, 56:163
- ambidexterity, schizophrenia, 59:119
- anhedonia, bipolar affective disorder, 56:163
- anhedonia, schizoaffective disorder, schizophrenia, 56:163
- anhedonia, skin conductance, 56:163
- bipolar affective disorder, anhedonia, 56:163
- memory, personality disorder, 56:71
- memory, schizotypal personality, 56:71
- motor activity, bipolar affective disorder, 57:279
- motor activity, schizophrenia, 57:279
- neuropsychology, memory, 56:71
- neuropsychology, personality disorder, 56:71
- neuropsychology, schizotypal personality, 56:71
- personality disorder, memory, 56:71
- personality disorder, neuropsychology, 56:71
- schizoaffective disorder, anhedonia, 56:163
- schizoaffective disorder, skin conductance, 56:163
- schizophrenia, ambidexterity, 59:119
- schizophrenia, anhedonia, 56:163
- schizophrenia, motor activity, 57:279
- schizophrenia, skin conductance, 56:163
- schizotypal personality, memory, 56:71
- skin conductance, affective disorder, anhedonia, 56:163
- skin conductance, schizoaffective disorder, schizophrenia, 56:163

**Light therapy**

- agitation, dementia, sundowning, 57:7

bulimia, depression, 60:1

- carbohydrate craving, circannual rhythm, 59:171
- carbohydrate craving, seasonal affective disorder, 59:171
- carbohydrate craving, taste detection, 59:171
- circadian rhythm, melatonin, 56:221
- circadian rhythm, seasonal affective disorder, 56:221
- circannual rhythm, carbohydrate craving, 59:171
- circannual rhythm, ethology, 57:223
- circannual rhythm, melatonin, 56:221
- circannual rhythm, seasonal affective disorder, 56:11, 56:221, 57:223, 59:171
- circannual rhythm, Southern Hemisphere, 56:11
- circannual rhythm, taste detection, 59:171
- dementia, agitation, sundowning, 57:7
- eating disorder, bulimia, depression, 60:1
- ethology, seasonal affective disorder, 57:223
- melatonin, circadian rhythm, circannual rhythm, 56:221
- melatonin, seasonal affective disorder, 56:221
- seasonal affective disorder, carbohydrate craving, 59:171
- seasonal affective disorder, circadian rhythm, 56:221
- seasonal affective disorder, circannual rhythm, 56:11, 56:221, 57:223, 59:171
- seasonal affective disorder, ethology, 57:223
- seasonal affective disorder, melatonin, 56:221
- seasonal affective disorder, Southern Hemisphere, 56:11
- seasonal affective disorder, taste detection, 59:171
- sundowning, agitation, dementia, 57:7
- taste detection, carbohydrate craving, circannual rhythm, 59:171
- taste detection, seasonal affective disorder, 59:171

**Magnetic resonance imaging**

- affective disorder, age, 60:117
- affective disorder, white matter hyperintensity, 60:117
- age, affective disorder, 60:117
- age, Alzheimer's Disease, 57:119
- age, brain volume, 57:119
- age, dementia, 57:119
- age, schizophrenia, 60:117
- age, temporal lobe, 57:119
- age, white matter hyperintensity, 60:117
- Alzheimer's Disease, brain volume, temporal lobe, 57:119
- Borna disease virus, putamen, 56:33
- brain volume, age, 57:119
- brain volume, Alzheimer's Disease, 57:119
- brain volume, dementia, 57:119
- brain volume, discriminant analysis, 57:119
- brain volume, sex, 57:119
- cavum septi pellucidi, posttraumatic stress disorder, 58:259
- dementia, age, 57:119
- dementia, brain volume, temporal lobe, 57:119
- discriminant analysis, brain volume, 57:119
- discriminant analysis, temporal lobe, 57:119
- elderly patients, affective disorder, schizophrenia, 60:117
- immunology, Borna disease virus, 56:33
- immunology, schizophrenia, 56:33
- late-life depression, white matter hyperintensity, 60:117

posttraumatic stress disorder, cavum septi pellucidi, 58:259  
putamen, Borna disease virus, 56:33  
putamen, schizophrenia, 56:33  
schizophrenia, age, 60:117  
schizophrenia, immunology, 56:33  
schizophrenia, putamen, 56:33  
schizophrenia, white matter hyperintensity, 60:117  
sex, Alzheimer's Disease, 57:119  
sex, brain volume, 57:119  
sex, dementia, 57:119  
temporal lobe, age, 57:119  
temporal lobe, Alzheimer's Disease, 57:119  
temporal lobe, dementia, 57:119  
temporal lobe, sex, 57:119  
white matter hyperintensity, affective disorder, schizophrenia, 60:117  
white matter hyperintensity, age, 60:117

#### **Magnetic resonance spectroscopy**

frontal cortex, phosphomonoesters, frontal cortex, schizophrenia, 57:91  
phosphomonoesters, frontal cortex, schizophrenia, 57:91  
schizophrenia, frontal cortex, phosphomonoesters, 57:91

#### **Mania. See Affective disorder (bipolar subtype)**

#### **Melatonin**

circadian rhythm, light therapy, seasonal affective disorder, 56:221  
circannual rhythm, light therapy, seasonal affective disorder, 56:221  
light therapy, circadian and circannual rhythms, 56:221  
pharmacokinetics, serotonin, platelets, 57:193  
seasonal affective disorder, circadian and circannual rhythms, 56:221  
seasonal affective disorder, light therapy, 56:221  
serotonin in platelets, pharmacokinetics, 57:193

#### **Memory**

adult survivors of child abuse, 59:97  
child abuse, Early Trauma Inventory, 59:97  
Early Trauma Inventory, adult survivors of child abuse, 59:97  
schizoaffective disorder, schizophrenia, 57:141  
schizophrenia, paired associate recognition, 60:135  
schizophrenia, schizoaffective disorder, 57:141

#### **Meningiomas**

neurologic signs, peritumoral edema, 58:177  
psychiatric morbidity, peritumoral edema, 58:177

#### **Meta-chlorophenylpiperazine**

borderline personality, serotonin, 58:161  
obsessive-compulsive disorder, serotonin, 58:161  
panic disorder, serotonin, 58:161  
personality disorder, serotonin, 58:161  
serotonin, borderline personality, obsessive-compulsive, panic, and personality disorders, social phobia, 58:161  
social phobia, serotonin, 58:161

#### **Metirapone**

comparison with dexamethasone administration, 58:23  
corticosteroid-dopaminergic interaction, 58:23  
homovanillic acid, cortisol, prolactin, 58:23

#### **Monoamine oxidase**

affective disorder, bipolar subtype, 59:165  
affective disorder, lithium treatment, 59:165  
aggression, dinucleotide repeat polymorphism, 59:35  
aggression, genetics, 59:35  
bipolar subtype, affective disorder, lithium treatment, 59:165  
conduct disorder, dinucleotide repeat polymorphism, 59:35  
dinucleotide repeat polymorphism, aggression, 59:35  
dinucleotide repeat polymorphism, conduct disorder, 59:35  
dinucleotide repeat polymorphism, genetics, 59:35  
dinucleotide repeat polymorphism, personality, 59:35  
dinucleotide repeat polymorphism, polymerase chain reaction, 59:35  
genetics, aggression, genetics, conduct disorder, personality type, 59:35  
genetics, polymerase chain reaction, 59:35  
lithium, affective disorder, bipolar subtype, 59:165  
personality type, aggression, 59:35  
platelets, affective disorder, bipolar subtype, 59:165  
polymerase chain reaction, dinucleotide repeat polymorphism, genetics, 59:35  
schizophrenia, deficit syndrome, negative symptoms, 56:25

#### **Monoamine oxidase inhibitor**

Alzheimer's Disease, cognition, 58:181  
cognition, Alzheimer's Disease, dementia, 58:181  
deprenyl, Alzheimer's Disease, dementia, 58:181  
physostigmine, Alzheimer's Disease, dementia, 58:181

#### **Motor activity**

affective disorder, bipolar subtype, laterality, 57:279  
bipolar subtype, affective disorder, laterality, 57:279  
laterality, affective disorder, bipolar subtype, 57:279  
laterality, schizophrenia, 57:279  
schizophrenia, laterality, 57:279

#### **BICNIC-acetyl- $\beta$ -glucosaminidase**

anxiety disorder, Profile of Mood States, 60:185  
panic disorder, Profile of Mood States, 60:185

#### **Naltrexone**

autism,  $\beta$ -endorphin, 58:191, 58:203  
autism, cortisol, social behavior, 58:203  
autism, treatment efficacy, 58:191, 58:203  
 $\beta$ -endorphin, autism, 58:191, 58:203  
 $\beta$ -endorphin, cortisol, social behavior, 58:203  
cortisol, autism,  $\beta$ -endorphin, social behavior, 58:203  
social behavior, autism,  $\beta$ -endorphin, cortisol, 58:203  
treatment efficacy in autism, 58:191, 58:203

#### **Neuroleptic effects**

attention, Continuous Performance Test, schizophrenia, 57:131



**Neurological symptoms**

- extrapyramidal signs, schizophrenia, 56:183
- motor coordination, schizophrenia, 56:183
- schizophrenia, Cambridge Neurological Inventory, 56:183

**Neuropsychology**

- adult survivors of child abuse, memory, 59:97
- attention, attention deficit hyperactivity disorder, 56:59
- attention deficit hyperactivity disorder, Stroop test, 56:59
- attention, schizophrenia, 56:111, 59:213
- attention, social cue perception, 56:111
- attention, social skill, 59:213
- attention, Stroop test, 56:59
- Brown-Peterson paradigm, frontal lobe, schizophrenia, 56:155
- child abuse survivors, memory performance, 59:97
- cocaine abuse, crack, 60:167
- cognition, cocaine abuse, crack, 60:167
- cognition, frontal lobe, 56:155, 60:167
- cognition, personality disorder, 59:127
- cognition, schizoaffective disorder, 56:45
- cognition, schizophrenia, 56:45, 56:155, 59:213
- cognition, schizotypal personality, 59:127
- cognition, sex effects, social skill, 59:213
- cognition, work performance, 56:45
- crack, cocaine, cognition, 60:167
- disorganization symptoms, schizophrenia, 58:227
- frontal lobe, Brown-Peterson paradigm, schizophrenia, 56:155
- frontal lobe, obsessive-compulsive disorder, 58:37
- frontal lobe, Wisconsin Card Sorting Test, 58:37
- genetics, IQ, matching fallacy, schizophrenia, 56:135
- IQ, genetics, schizophrenia, 56:135
- laterality, memory, 56:71
- laterality, personality disorder, 56:71
- laterality, schizotypal personality, 56:71
- matching fallacy, IQ, schizophrenia, 56:135
- memory, adult survivors of child abuse, 59:97
- memory, laterality, 56:71
- memory, paired associate recognition, 60:135
- memory, personality disorder, 56:71
- memory, schizophrenia, 56:155, 60:135
- memory, schizotypal personality, 56:71
- negative symptoms, schizoaffective disorder, 58:45
- negative symptoms, schizophrenia, 58:45, 58:227
- negative symptoms, Wisconsin Card Sorting Test, 58:45
- obsessive-compulsive disorder, frontal lobe, 58:37
- obsessive-compulsive disorder, Wisconsin Card Sorting Test, 58:37
- paired associate recognition, schizophrenia, 60:135
- personality disorder, cognition, 59:127
- personality disorder, laterality, 56:71
- personality disorder, memory, 56:71
- positive symptoms, schizoaffective disorder, 58:45
- positive symptoms, schizophrenia, 58:45, 58:227
- positive symptoms, Wisconsin Card Sorting Test, 58:45
- schizoaffective disorder, cognition, 56:45
- schizoaffective disorder, positive and negative symptoms, 58:45
- schizoaffective disorder, Wisconsin Card Sorting Test, 56:45
- schizoaffective disorder, work performance, 56:45

- schizophrenia, attention, 56:111, 59:213
- schizophrenia, Brown-Peterson paradigm, 56:155
- schizophrenia, cognition, 56:45, 56:155, 59:213
- schizophrenia, disorganization symptoms, 58:227
- schizophrenia, frontal lobe, 56:155
- schizophrenia, genetics, IQ, matching fallacy, 56:135
- schizophrenia, memory, 56:155, 60:135
- schizophrenia, paired associate recognition, 60:135
- schizophrenia, positive and negative symptoms, 58:45, 58:227
- schizophrenia, sex effects, 59:213
- schizophrenia, social cue perception, 56:111
- schizophrenia, social skill, 59:213
- schizophrenia, Wisconsin Card Sorting Test, 58:45, 60:135
- schizophrenia, work performance, 56:45
- schizotypal personality, cognition, 59:127
- schizotypal personality, laterality, 56:71
- schizotypal personality, memory, 56:71
- sex effects, attention, cognition, social skill, schizophrenia, 59:213
- social cue perception, schizophrenia, 56:111
- social skill, attention, cognition, sex effects, schizophrenia, 59:213
- Stroop test, attention deficit hyperactivity disorder, 56:59
- substance dependence, crack cocaine, cognition, 60:167
- Wisconsin Card Sorting Test, cognition, 56:45
- Wisconsin Card Sorting Test, frontal lobe, 58:37
- Wisconsin Card Sorting Test, memory, 60:135
- Wisconsin Card Sorting Test, negative symptoms, 58:45
- Wisconsin Card Sorting Test, obsessive-compulsive disorder, 58:37
- Wisconsin Card Sorting Test, positive symptoms, 58:45
- Wisconsin Card Sorting Test, schizoaffective disorder, 56:45
- Wisconsin Card Sorting Test, schizophrenia, 56:45, 58:45, 60:135
- Wisconsin Card Sorting Test, work performance, 56:45
- work performance, cognition, schizoaffective disorder, schizophrenia, 56:45
- work performance, Wisconsin Card Sorting Test, 56:45

**Norepinephrine**

- anxiety disorder, vanillylmandelic acid, 57:1
- blood pressure, body temperature, heart rate, 57:21
- circadian rhythm, schizophrenia, 57:21
- schizophrenia, circadian rhythm, 57:21
- vanillylmandelic acid, anxiety disorder, 57:1
- Obsessive-compulsive disorder
- adolescents, children, 60:67
- affective disorder, comorbidity, 59:57
- anxiety, cholinesterase, 58:265
- checking rituals, obsessive stimulation, positron emission tomography, 60:101
- children, adolescents, 60:67
- cholinesterase, anxiety, 58:265
- epidemiology, comorbid disorders, 59:57
- fluvoxamine, cholinesterase, 58:265
- frontal lobe, Wisconsin Card Sorting Test, 58:37
- heart rate, adolescents, children, 60:67
- meta-chlorophenylpiperazine, serotonin, 58:161

neuropsychology, frontal lobe, 58:37  
 obsessive stimulation, checking rituals, positron emission tomography, 60:101  
 paroxetine binding, platelet, 58:117  
 positron emission tomography, checking rituals, obsessive stimulation, 60:101  
 serotonin, meta-chlorophenylpiperazine, 58:161  
 serotonin, paroxetine binding, platelet, 58:117  
 skin conductance, adolescents, children, 60:67  
 tic disorder, adolescents, children, 60:67  
 Wisconsin Card Sorting Test, frontal lobe, 58:37

#### **Ondansetron**

affective disorder, electroconvulsive therapy, prolactin, serotonin, 60:33  
 electroconvulsive therapy, affective disorder, prolactin, serotonin, 60:33  
 prolactin, affective disorder, electroconvulsive therapy, 60:33  
 serotonin, affective disorder, electroconvulsive therapy, 60:33

#### **Opiates. See Beta-endorphin; Naltrexone; Peptides**

#### **Pain**

bipolar affective disorder, signal detection, stimulus intensity, 56:173  
 signal detection, stimulus intensity, bipolar affective disorder, 56:173

#### **Panic disorder**

Acute Panic Inventory, panic attacks, 58:127  
 agoraphobia, behavior therapy, 56:1  
 agoraphobia, carbon dioxide inhalation, 57:267  
 animal model, anxiety disorder, 57:181  
 behavior therapy, agoraphobia, 56:1  
 blood pressure, lactate, 58:127  
 blood pressure, panic attacks, 58:127  
 carbon dioxide inhalation, agoraphobia, panic attacks, 57:267  
 diazepam, panic attacks, 58:127  
 heart rate, isoproterenol, 56:289  
 heart rate, spectral analysis, 56:289  
 isoproterenol, heart rate, 56:289  
 isoproterenol, sympathovagal ratio, 56:289  
 lactate infusion, Acute Panic Inventory, 58:127  
 lactate infusion, blood pressure, 58:127  
 lactate infusion, diazepam, 58:127  
 lactate infusion, panic attacks, 58:127  
 meta-chlorophenylpiperazine, serotonin, 58:161  
 N-acetyl- $\beta$ -glucosaminidase, anxiety, Profile of Mood States, 60:185  
 neuropeptide Y, norepinephrine, stress, 59:183  
 norepinephrine, neuropeptide Y, stress, 59:183  
 panic attacks, Acute Panic Inventory, 58:127  
 panic attacks, agoraphobia, 57:267  
 panic attacks, blood pressure, 58:127  
 panic attacks, carbon dioxide inhalation, 57:267  
 panic attacks, diazepam, 58:127  
 panic attacks, lactate infusion, 58:127  
 peptides, norepinephrine, 59:183

peptides, stress, 59:183

Profile of Mood States, anxiety, N-acetyl- $\beta$ -glucosaminidase, 60:185

rat, animal model of anxiety-panic, alprazolam, clonazepam, yohimbine, 57:181

rat, dorsal periaqueductal gray matter, intracerebral stimulation, 57:181

serotonin, meta-chlorophenylpiperazine, 58:161

spectral analysis, heart rate, 56:289

stress, neuropeptide Y, stress, norepinephrine, 59:183

sympathovagal ratio, heart rate, isoproterenol, 56:289

yohimbine, animal model of panic-anxiety, 57:181

#### **Paroxetine**

affective disorder, imipramine, 59:189  
 affective disorder, serotonin, 58:117, 59:189  
 calcium, cortisol, serotonin, impulsivity, 60:177  
 cortisol, calcium, serotonin, impulsivity, 60:177  
 imipramine pharmacokinetics, affective disorder, 59:189  
 impulsivity, calcium, cortisol, serotonin, 60:177  
 obsessive-compulsive disorder, serotonin, 58:117  
 personality characteristics, calcium, cortisol, serotonin, 60:177  
 pharmacokinetics, imipramine, 59:189  
 serotonin, affective disorder, 58:117, 59:189  
 serotonin, calcium, cortisol, impulsivity, 60:177  
 serotonin, obsessive-compulsive disorder, 58:117  
 serotonin, personality characteristics, 60:177  
 serotonin, platelet measures, 58:117

#### **Peptides**

affective disorder, mania, 58:217  
 affective disorder, prolyl endopeptidase, 58:217  
 anorexia,  $\beta$ -endorphin, T-lymphocytes, 59:43  
 anorexia, cholecystokinin-8, T-lymphocytes, 59:43  
 anxiety disorder, neuropeptide Y, 59:183  
 $\beta$ -endorphin, anorexia, 59:43  
 $\beta$ -endorphin, bulimia, 59:51  
 $\beta$ -endorphin, cholecystokinin-8, 59:51  
 $\beta$ -endorphin, T-lymphocytes, 59:51  
 bulimia,  $\beta$ -endorphin, 59:51  
 bulimia, cholecystokinin-8, 59:51  
 cholecystokinin-8, anorexia, 59:43  
 cholecystokinin-8, bulimia, 59:51  
 eating disorder,  $\beta$ -endorphin, 59:43, 59:51  
 eating disorder, cholecystokinin-8, 59:43, 59:51  
 T-lymphocytes,  $\beta$ -endorphin and cholecystokinin-8, 59:43, 59:51  
 mania, prolyl endopeptidase, 58:217  
 neuropeptide Y, panic-anxiety, 59:183  
 neuropeptide Y, social phobia, 59:183  
 neuropeptide Y, stress, 59:183  
 panic disorder, neuropeptide Y, 59:183  
 panic disorder, stress, 59:183  
 prolyl endopeptidase, affective disorder, mania, 58:217  
 prolyl endopeptidase, schizophrenia, 58:217  
 schizophrenia, prolyl endopeptidase, 58:217  
 social phobia, neuropeptide Y, 59:183  
 social phobia, stress, 59:183

stress, anxiety disorder, 59:183  
 stress, neuropeptide Y, 59:183  
 stress, panic disorder, 59:183  
 stress, social phobia, 59:183  
 T-lymphocytes,  $\beta$ -endorphin and cholecystokinin-8, eating disorder, 59:43, 59:51

**Personality disorder.** *See also* Schizotypal personality

attention, backward masking, 60:49  
 attention, Continuous Performance Test, 60:49  
 backward masking, attention, cognition, 60:49  
 borderline personality, meta-chlorophenylpiperazine, 58:161  
 borderline personality, serotonin, 58:161  
 bufotenin, serotonin, 58:145  
 bufotenin, violence, 58:145  
 cognition, neuropsychology, 59:127  
 computed tomography, ventricle-brain ratio, 57:109  
 Continuous Performance Test, attention, 60:49  
 harm avoidance, Tridimensional Personality Questionnaire, 57:209  
 laterality, memory, neuropsychology, 56:71  
 memory, laterality, 56:71  
 meta-chlorophenylpiperazine, borderline personality, 58:161  
 meta-chlorophenylpiperazine, serotonin, 58:161  
 neuropsychology, cognition, 59:127  
 neuropsychology, laterality, memory, 56:71  
 serotonin, borderline personality, 58:161  
 serotonin, bufotenin, 58:145  
 serotonin, impulsivity, 60:177  
 serotonin, meta-chlorophenylpiperazine, 58:161  
 serotonin, violence, 58:145  
 Tridimensional Personality Questionnaire, harm avoidance, 57:209  
 ventricle-brain ratio, computed tomography, 57:109  
 violence, bufotenin, serotonin, 58:145

**Phospholipase A2**

animal model, rat, 58:165  
 apomorphine, dopamine, 58:165  
 dopamine, apomorphine, 58:165

**Phosphomonoesters**

frontal cortex, magnetic resonance spectroscopy, schizophrenia, 57:91  
 magnetic resonance spectroscopy, frontal cortex, schizophrenia, polysomnography, 57:91  
 schizophrenia, frontal cortex, magnetic resonance spectroscopy, polysomnography, 57:91

**Phototherapy.** *See* Light therapy

**Physostigmine**

Alzheimer's Disease, cognition, deprenyl, 58:181  
 cognition, Alzheimer's Disease, deprenyl, 58:181  
 cognition, dementia, deprenyl, 58:181  
 dementia, cognition, deprenyl, 58:181  
 deprenyl, Alzheimer's Disease, dementia, cognition, 58:181

**Pindolol**

cortisol, meta-chlorophenylpiperazine, 58:89  
 meta-chlorophenylpiperazine, cortisol, prolactin, serotonin, 58:89  
 prolactin, meta-chlorophenylpiperazine, 58:89  
 serotonin, meta-chlorophenylpiperazine, 58:89

**Polysomnography**

affective disorder, period amplitude vs. power spectral analysis, 56:245  
 Lyapunov exponent, nonlinear analysis, 56:257  
 Lyapunov exponent, rapid eye movement sleep, 56:257  
 Lyapunov exponent, schizophrenia, 56:257  
 nonlinear analysis, Lyapunov exponent, rapid eye movement, schizophrenia, 56:257  
 period amplitude vs. power spectral analysis, affective disorder, 56:245  
 rapid eye movement, Lyapunov exponent, nonlinear analysis, schizophrenia, 56:257  
 rapid eye movement, slow wave sleep, 59:203  
 schizophrenia, Lyapunov exponent, nonlinear analysis, 56:257  
 schizophrenia, rapid eye movement, 56:257, 59:203  
 schizophrenia, slow wave sleep, 57:91, 59:203, 60:125  
 slow wave sleep, computed tomography, ventricle-brain ratio, 60:125  
 slow wave sleep, magnetic resonance spectroscopy, 57:91  
 slow wave sleep, schizophrenia, 57:91, 59:203, 60:125

**Positron emission tomography**

caudate nucleus, electrooculography, frontal eye fields, schizophrenia, 58:53  
 checking rituals, obsessive stimulation, obsessive-compulsive disorder, 60:101  
 electrooculography, caudate nucleus, frontal eye fields, schizophrenia, 58:53  
 extrapyramidal symptoms, haloperidol, 60:91  
 eye movements, frontal eye fields, smooth pursuit tracking, schizophrenia, 58:53  
 frontal eye fields, caudate nucleus, electrooculography, schizophrenia, 58:53  
 haloperidol, extrapyramidal symptoms, 60:91  
 obsessive stimulation, checking rituals, obsessive-compulsive disorder, 60:101  
 obsessive-compulsive disorder, checking rituals, obsessive stimulation, 60:101  
 olfaction, olfactory projections, orbitofrontal cortex, schizophrenia, 60:113  
 olfactory projections, orbitofrontal cortex, schizophrenia, 60:113  
 orbitofrontal cortex, olfaction, olfactory projections, schizophrenia, 60:113  
 schizophrenia, caudate nucleus, eye movements, frontal eye fields, 58:53  
 schizophrenia, olfactory projections, orbitofrontal cortex, 60:113

**Posttraumatic stress disorder**

- cavum septi pellucidi, magnetic resonance imaging, 58:259
- magnetic resonance imaging, cavum septi pellucidi, 58:259

**Prolactin**

- abstinence, alcohol dependence, 56:81
- affective disorder, ondansetron, 60:33
- alcohol dependence, abstinence, 56:81
- dopamine, homovanillic acid, 58:23
- dopamine, metyrapone, 58:23
- fenfluramine, substance dependence, 58:153
- heroin abuse, fenfluramine, 58:153
- homovanillic acid, dopamine, 58:23
- ondansetron, affective disorder, 60:33
- pindolol, meta-chlorophenylpiperazine, 58:89
- substance dependence, comorbid depression, 58:153

**Prolyl endopeptidase**

- affective disorder, mania, schizophrenia, 58:217

**Rat. See Animal models****BICSIC-adenosylmethionine**

- affective disorder, antidepressant effect, 56:295
- antidepressant effect, affective disorder, 56:295

**Schizoaffective disorder. See Schizophrenia****Schizophrenia. See also Schizotypal personality**

- Abnormal Involuntary Movements Scale, circadian rhythm, 56:53
- Abnormal Involuntary Movements Scale, haloperidol, 56:53
- Abnormal Involuntary Movements Scale, tardive dyskinesia, 56:53
- age, magnetic resonance imaging, 60:117
- age of onset, anticipation, 59:25
- age of onset, genetics, 59:25
- age, white matter hyperintensity, 60:117
- Allen Cognitive Levels, cross-cultural, African-American, Mexican-American, 56:101
- ambidexterity, laterality, 59:119
- anhedonia, laterality, 56:163
- anhedonia, skin conductance, 56:163
- anticipation, age of onset, 59:25
- anticipation, genetics, 59:25
- arachidonic acid, phospholipids, 60:11
- attention, backward masking, 60:49
- attention, Continuous Performance Test, 57:131, 60:49, 60:155
- attention, disorganized symptoms, 57:241
- attention, evoked potentials, P300 component, 58:69
- attention, eye movements, 59:221
- attention, heart rate, 57:241
- attention, negative symptoms, 57:241
- attention, neuroleptic effects, 57:131
- attention, Pigache Attention Task, 60:155
- attention, positive symptoms, 57:241
- attention, reaction time, 58:69
- attention, sex differences, 59:213
- attention, skin conductance, 57:241

- attention, social cue perception, 56:111
- attention, social skill, 59:213
- attention, tardive dyskinesia, 59:221
- attention, tone discrimination, 57:75
- backward masking, attention, cognition, 60:49
- blood pressure, body temperature, 57:21
- blood pressure, circadian rhythm, 57:21
- blood pressure, heart rate, 57:21
- blood pressure, norepinephrine, 57:21
- body temperature, circadian rhythm, 57:21
- Borna Disease virus, magnetic resonance imaging, 56:33
- Brown-Peterson paradigm, frontal lobe, 56:155
- calbindin, frontal lobe, local circuit neurons, 59:81
- calbindin,  $\gamma$ -aminobutyric acid, 59:81
- calretinin, frontal lobe, local circuit neurons, 59:81
- calretinin,  $\gamma$ -aminobutyric acid, 59:81
- Cambridge Neurological Inventory, extrapyramidal signs, motor coordination, soft signs, 56:183
- catatonic subtype, genetics, pseudoautosomal inheritance, 59:17
- catatonic subtype, sex concordance, 59:17
- caudate nucleus, positron emission tomography, 58:53
- circadian rhythm, blood pressure, 57:21
- circadian rhythm, body temperature, 57:21
- circadian rhythm, cortisol, 57:21
- circadian rhythm, heart rate, 57:21
- circadian rhythm, norepinephrine, 57:21
- circadian rhythm, thyroid hormones, 57:21
- circadian rhythm, Abnormal Involuntary Movements Scale, 56:53
- circadian rhythm, photoperiod, 60:199
- circadian rhythm, tardive dyskinesia, 56:53
- circadian rhythm, violence, 60:199
- circannual rhythm, photoperiod, 60:199
- circannual rhythm, violence, 60:199
- cognition, Allen Cognitive Levels, 56:101
- cognition, attention, 59:213
- cognition, attention, 60:49
- cognition, attention, 60:147
- cognition, backward masking, 60:49
- cognition, Brown-Peterson paradigm, 56:155
- cognition, cross-cultural, 56:101
- cognition, frontal lobe, 56:155
- cognition, memory, 56:155, 57:141
- cognition, Selective Attention Test, 60:147
- cognition, social skill, 57:141, 59:213
- cognition, Wisconsin Card Sorting Test, 56:45
- cognition, work performance, 56:45
- communication deviance, expressed emotion, 56:121
- communication deviance, family interactions, 56:121
- communication deviance, prognosis, 56:121
- communication deviance, schizoaffective disorder, 56:121
- communication deviance, social skills, 56:121
- computed tomography, schizotypal personality disorder, 57:109
- computed tomography, ventricle-brain ratio, 57:109, 60:147
- content analysis, expressed emotion, 57:155
- content analysis, family environment, 57:155

- content analysis, speech, 57:155
- Continuous Performance Test, attention, 57:131, 60:49, 60:155
- Continuous Performance Test, backward masking, 60:49
- Continuous Performance Test, distractibility, 57:131
- Continuous Performance Test, neuroleptic effects, 57:131
- Continuous Performance Test vs. Pigache Attention Task, 60:155
- cortisol, circadian rhythm, 57:21
- cross-cultural, Allen Cognitive Levels, African-American, Mexican-American, 56:101
- deficit syndrome, monoamine oxidase, 56:25
- disorganization symptoms, neuropsychology, 58:227
- disorganized symptoms, attention, 57:241
- disorganized symptoms, heart rate, 57:241
- disorganized symptoms, skin conductance, 57:241
- dopamine transporter gene, French population, 59:1
- dopamine transporter gene, linkage analysis, 59:1
- elderly patients, magnetic resonance imaging, 60:117
- elderly patients, white matter hyperintensity, 60:117
- electroencephalography, evoked potentials, 56:229, 56:237, 56:271
- electroencephalography, Lyapunov exponent, nonlinear analysis, 56:257
- electroencephalography, P50 evoked potential component, 56:271
- electrooculography, frontal eye fields, positron emission tomography, 58:53
- epidemiology, season of birth, 60:205
- epidemiology, Southern Hemisphere, 60:205
- evoked potentials, attention, 58:69
- evoked potentials, gating, 56:271
- evoked potentials, late component, 56:229
- evoked potentials, oddball paradigm, 56:237
- evoked potentials, P300 component, 58:69
- evoked potentials, P50 component, 56:271
- evoked potentials, reaction time, 58:69
- evoked potentials, variance, medication effects, 56:229, 56:237
- expressed emotion, communication deviance, 56:121
- expressed emotion, content analysis, 57:155
- expressed emotion, family environment, 57:155
- expressed emotion, family interactions, 56:121
- expressed emotion, prognosis, 56:121
- expressed emotion, social skills, 56:121
- expressed emotion, speech analysis, 57:155
- extrapyramidal signs, Cambridge Neurological Inventory, 56:183
- extrapyramidal signs, motor coordination, 56:183
- extrapyramidal signs, neurological soft signs, 56:183
- eye movements, attention, 59:221
- eye movements, caudate nucleus, positron emission tomography, 58:53
- eye movements, smooth pursuit, 58:53, 59:221
- eye movements, tardive dyskinesia, 59:221
- family environment, expressed emotion, 57:155
- family interactions, communication deviance, 56:121
- family interactions, expressed emotion, 56:121
- family interactions, prognosis, 56:121
- family interactions, social skills, 56:121
- French population, dopamine transporter gene, 59:1
- French population, linkage analysis, 59:1
- frontal cortex, magnetic resonance spectroscopy, 57:91
- frontal cortex, phosphomonoesters, 57:91
- frontal eye fields, caudate nucleus, 58:53
- frontal eye fields, positron emission tomography, 58:53
- frontal lobe, Brown-Peterson paradigm, 56:155
- frontal lobe, calbindin, calretinin, 59:81
- frontal lobe, cognition, 56:155
- frontal lobe,  $\gamma$ -aminobutyric acid, 59:81
- frontal lobe, local circuit neurons, 59:81
- frontal lobe, memory, 56:155
- frontal lobe, neuropsychology, 56:155
- frontal lobe, post-mortem study, 59:81
- $\gamma$ -aminobutyric acid, calbindin, calretinin, 59:81
- $\gamma$ -aminobutyric acid, frontal lobe, 59:81
- $\gamma$ -aminobutyric acid, local circuit neurons, 59:81
- $\gamma$ -aminobutyric acid, post-mortem study, 59:81
- gating, evoked potentials, P50 component, 56:271
- genetics, age of onset, 59:25
- genetics, anticipation, 59:25
- genetics, catatonic subtype, 59:17
- genetics, dopamine transporter gene, French population, 59:1
- genetics, IQ, 56:135
- genetics, linkage analysis, 59:1
- genetics, pseudoautosomal inheritance, 59:17
- genetics, sex concordance, 59:17
- gonadotropin, gonadotropin-releasing hormone, luteinizing hormone, testosterone, 57:231
- gonadotropin-releasing hormone, gonadotropin, luteinizing hormone, testosterone, 57:231
- haloperidol, Abnormal Involuntary Movements Scale, 56:53
- haloperidol, circadian rhythm, 56:53
- haloperidol, positive and negative symptoms, 57:49
- haloperidol, skin conductance, 57:49
- haloperidol, tardive dyskinesia, 56:53
- haloperidol, ketone reductase, 57:101
- haloperidol, reduced haloperidol, 57:101
- heart rate, attention, 57:241
- heart rate, blood pressure, body temperature, 57:21
- heart rate, circadian rhythm, 57:21
- 5-hydroxyindoleacetic acid, meta-analysis, 59:239
- 5-hydroxyindoleacetic acid, serotonin, 59:161, 59:239
- 5-hydroxyindoleacetic acid, violence, 59:161
- immunology, Borna Disease virus, 56:33
- immunology, magnetic resonance imaging, 56:33
- IQ, genetics, matching fallacy, neuropsychology, 56:135
- ketone reductase, haloperidol, 57:101
- ketone reductase, reduced haloperidol, 57:101
- laterality, ambidexterity, 59:119
- laterality, anhedonia, 56:163
- laterality, motor activity, 57:279
- laterality, skin conductance, 56:163
- linkage analysis, dopamine transporter gene, French population, 59:1
- luteinizing hormone, gonadotropin-releasing hormone, 57:231
- luteinizing hormone, testosterone, 57:231



- Lyapunov exponent, electroencephalography, nonlinear analysis, 56:257
- Lyapunov exponent, polysomnography, rapid eye movement sleep stage, 56:257
- magnetic resonance imaging, age, 60:117
- magnetic resonance imaging, Borna disease virus, 56:33
- magnetic resonance imaging, elderly patients, 60:117
- magnetic resonance imaging, putamen, 56:33
- magnetic resonance imaging, white matter hyperintensity, 60:117
- magnetic resonance spectroscopy, frontal cortex, phosphomonoesters, 57:91
- memory, 56:155, 57:141, 60:135
- meta-analysis, hydroxyindoleacetic acid, 59:239
- milieu therapy, neuroleptic treatment, outcome prediction, 58:77
- milieu therapy, paranoid subtype, 58:77
- milieu therapy, patients' global assessments, 58:77
- monoamine oxidase, deficit syndrome, negative symptoms, 56:25
- motor activity, laterality, 57:279
- motor coordination, Cambridge Neurological Inventory, 56:183
- negative symptoms, attention, 57:241
- negative symptoms, deficit syndrome, 56:25
- negative symptoms, diagnosis, 56:25
- negative symptoms, haloperidol, 57:49
- negative symptoms, heart rate, 57:241
- negative symptoms, monoamine oxidase, 56:25
- negative symptoms, neuropsychology, 58:45, 58:227
- negative symptoms, skin conductance, 57:49, 57:241
- negative symptoms, Wisconsin Card Sorting Test, 58:45
- neuroleptic effects, attention, 57:131
- neuroleptic effects, Continuous Performance Test, 57:131
- neuroleptic effects, distractibility, 57:131
- neuroleptic effects, evoked potentials, 56:229
- neuroleptic treatment, milieu therapy, 58:77
- neuroleptic treatment, outcome prediction, 58:77
- neuroleptic treatment, paranoid subtype, 58:77
- neuroleptic treatment, patients' global assessments, 58:77
- neuroleptic treatment, peptides, 58:171
- neurological soft signs, Cambridge Neurological Inventory, 56:183
- neuropsychology, attention, 56:111, 59:213
- neuropsychology, Brown-Peterson paradigm, 56:155
- neuropsychology, cognition, 56:45, 56:155, 59:213
- neuropsychology, disorganization symptoms, 58:227
- neuropsychology, frontal lobe, 56:155
- neuropsychology, genetics, IQ, matching fallacy, 56:135
- neuropsychology, memory, 56:155, 60:135
- neuropsychology, negative symptoms, 58:45, 58:227
- neuropsychology, paired associate recognition, 60:135
- neuropsychology, positive symptoms, 58:45, 58:227
- neuropsychology, social cue perception, 56:111
- neuropsychology, social skill, 59:213
- neuropsychology, Wisconsin Card Sorting Test, 56:45, 58:45, 60:135
- neuropsychology, work performance, 56:45
- nonlinear analysis, electroencephalography, Lyapunov exponent, 56:257
- nonlinear analysis, polysomnography, rapid eye movement sleep stage, 56:257
- norepinephrine, blood pressure, circadian rhythm, 57:21
- olfactory projections, orbitofrontal cortex, positron emission tomography, 60:113
- orbitofrontal cortex, olfactory projections, positron emission tomography, 60:113
- outcome prediction, milieu therapy, neuroleptic treatment, 58:77
- outcome prediction, paranoid subtype, 58:77
- outcome prediction, patients' global assessments, 58:77
- outcome, role in diagnosis, 59:109
- outcome, schizophreniform disorder, 59:109
- paired associate recognition, neuropsychology, 60:135
- paranoid subtype, milieu therapy, neuroleptic treatment, 58:77
- paranoid subtype, outcome prediction, 58:77
- paranoid subtype, patients' global assessments, 58:77
- phospholipids, arachidonic acid, 60:11
- phosphomonoesters, frontal cortex, magnetic resonance spectroscopy, 57:91
- photoperiod, circadian and circannual rhythm, 60:199
- photoperiod, violence, 60:199
- Pigache Attention Task vs. Continuous Performance Test, 60:155
- polysomnography, computed tomography, 60:125
- polysomnography, Lyapunov exponent, 56:257
- polysomnography, magnetic resonance spectroscopy, 57:91
- polysomnography, nonlinear analysis, 56:257
- polysomnography, rapid eye movement sleep stage, 56:257, 59:203
- polysomnography, slow wave sleep, 57:91, 59:203, 60:125
- positive symptoms, attention, 57:241
- positive symptoms, haloperidol, 57:49
- positive symptoms, heart rate, 57:241
- positive symptoms, neuropsychology, 58:45, 58:227
- positive symptoms, skin conductance, 57:49, 57:241
- positive symptoms, Wisconsin Card Sorting Test, 58:45
- positron emission tomography, caudate nucleus, frontal eye fields, 58:53
- positron emission tomography, olfaction, orbitofrontal cortex, 60:113
- prognosis, communication deviance, expressed emotion, family interactions, 56:121
- prognosis, social skills, 56:121
- prolyl endopeptidase, 58:217
- pseudoautosomal inheritance, catatonic subtype, sex concordance, 59:17
- putamen, Borna Disease virus, magnetic resonance imaging, 56:33
- rapid eye movement sleep, 56:257, 56:271, 59:203
- reaction time, attention, evoked potential P300 component, 58:69
- reduced haloperidol, ketone reductase, 57:101
- schizoaffective disorder, Allen Cognitive Levels, 56:101
- schizoaffective disorder, anhedonia, 56:163
- schizoaffective disorder, attention, 57:241

schizoaffective disorder, cognition, 56:45, 56:101, 57:141  
 schizoaffective disorder, communication deviance, 56:121  
 schizoaffective disorder, cross-cultural comparison, African-American, Mexican-American, 56:101  
 schizoaffective disorder, disorganized symptoms, 57:241  
 schizoaffective disorder, expressed emotion, family interactions, 56:121  
 schizoaffective disorder, heart rate, 57:241  
 schizoaffective disorder, laterality, 56:163  
 schizoaffective disorder, memory, 57:141  
 schizoaffective disorder, negative symptoms, 57:241, 58:45  
 schizoaffective disorder, neuropsychology, 56:45  
 schizoaffective disorder, neuropsychology, 58:45  
 schizoaffective disorder, positive symptoms, 57:241, 58:45  
 schizoaffective disorder, prognosis, 56:121  
 schizoaffective disorder, sex, 57:141  
 schizoaffective disorder, skin conductance, 56:163, 57:241  
 schizoaffective disorder, social skill, 56:121, 57:141  
 schizoaffective disorder, Wisconsin Card Sorting Test, 56:45  
 schizoaffective disorder, work performance, 56:45  
 schizophreniform disorder, diagnosis, outcome, 59:109  
 season of birth, epidemiology, Southern Hemisphere, 60:205  
 Selective Attention Test, 60:147  
 serotonin, 5-hydroxyindoleacetic acid, 59:161, 59:239  
 serotonin, meta-analysis, statistics, 59:239  
 serotonin, violence, 59:161  
 sex concordance, catatonic subtype, 59:17  
 skin conductance, anhedonia, 56:163  
 skin conductance, attention, 57:241  
 skin conductance, disorganized symptoms, 57:241  
 skin conductance, haloperidol, 57:49  
 skin conductance, laterality, 56:163  
 skin conductance, negative symptoms, 57:49, 57:241  
 skin conductance, positive symptoms, 57:49, 57:241  
 skin conductance, schizoaffective disorder, 56:163, 57:241  
 sleep, computed tomography, 60:125  
 sleep, evoked potentials, P50 component, 56:271  
 sleep, frontal cortex, 57:91  
 sleep, gating, 56:271  
 sleep, Lyapunov exponent, nonlinear analysis, 56:257  
 sleep, magnetic resonance spectroscopy, phosphomonoesters, 57:91  
 sleep, rapid eye movement, 56:257, 56:271, 59:203  
 sleep, slow wave sleep, 56:271, 57:91, 59:203, 60:125  
 sleep, ventricle-brain ratio, 60:125  
 slow wave sleep, computed tomography, ventricle-brain ratio, 60:125  
 slow wave sleep, evoked potentials, 56:271  
 slow wave sleep, frontal cortex, 57:91  
 slow wave sleep, gating, 56:271  
 slow wave sleep, magnetic resonance spectroscopy, phosphomonoesters, 57:91  
 social cue perception, neuropsychology, 56:111  
 social skill, attention, 59:213  
 social skill, cognition, 57:141, 59:213  
 social skill, communication deviance, 56:121  
 social skill, expressed emotion, 56:121  
 social skill, family interactions, 56:121

social skill, memory, 57:141  
 social skill, neuropsychology, 59:213  
 social skills, prognosis, 56:121  
 speech, content analysis, expressed emotion, family environment, 57:155  
 statistics, meta-analysis, 5-hydroxyindoleacetic acid, serotonin, 59:239  
 tardive dyskinesia, Abnormal Involuntary Movements Scale, 56:53  
 tardive dyskinesia, attention, 59:221  
 tardive dyskinesia, circadian rhythm, 56:53  
 tardive dyskinesia, eye movements, smooth pursuit tracking, 59:221  
 testosterone, gonadotropin, gonadotropin releasing hormone, luteinizing hormone, 57:231  
 thyroid hormones, circadian rhythm, 57:21  
 tone discrimination, attention, 57:75  
 valproate, prolidase, 58:217  
 ventricle-brain ratio, computed tomography, 57:109, 60:125  
 violence, circadian and circannual rhythm, 60:199  
 violence, 5-hydroxyindoleacetic acid, 59:161  
 violence, photoperiod, 60:199  
 violence, serotonin, 59:161  
 white matter hyperintensity, age, 60:117  
 white matter hyperintensity, elderly patients, 60:117  
 white matter hyperintensity, magnetic resonance imaging, 60:117  
 Wisconsin Card Sorting Test, positive and negative symptoms, 58:45  
 Wisconsin Card Sorting Test, schizoaffective disorder, 56:45, 58:45  
 Wisconsin Card Sorting Test, work performance, 56:45  
 work performance, neuropsychology, 56:45  
 work performance, schizoaffective disorder, 56:45  
 work performance, Wisconsin Card Sorting Test, 56:45

#### Schizophreniform disorder. *See* Schizophrenia

#### Schizotypal personality

attention, backward masking, Continuous Performance Test, 60:49  
 backward masking, attention, 60:49  
 cognition, neuropsychology, 59:127  
 computed tomography, ventricle-brain ratio, 57:109  
 Continuous Performance Test, attention, 60:49  
 laterality, memory, 56:71  
 laterality, neuropsychology, 56:71  
 memory, laterality, 56:71  
 memory, neuropsychology, 56:71  
 neuropsychology, cognition, 59:127  
 neuropsychology, laterality, 56:71  
 neuropsychology, memory, 56:71  
 ventricle-brain ratio, computed tomography, 57:109

#### Serotonin

affective disorder, computed tomography, 60:33  
 affective disorder, paroxetine, 58:117, 59:189  
 alcohol dependence, intracellular calcium, 57:275  
 Alzheimer's Disease, pharmacokinetics, platelets, 59:145

- anxiety disorder, 5-hydroxyindoleacetic acid, 57:1  
 attention deficit hyperactivity disorder, oppositional-defiant disorder, 57:13  
 autism,  $\beta$ -endorphin, naltrexone, 58:191  
 $\beta$ -endorphin, autism, 58:191  
 borderline personality, meta-chlorophenylpiperazine, 58:161  
 bufotenin, personality, violence, 58:145  
 computed tomography, affective disorder, 60:33  
 conduct disorder, oppositional-defiant disorder, 57:13  
 dementia, pharmacokinetics, platelets, 59:145  
 genetics, attention deficit hyperactivity disorder, conduct disorder, oppositional-defiant disorder, 57:13  
 5-hydroxyindoleacetic acid, anxiety disorder, 57:1  
 5-hydroxyindoleacetic acid, meta-analysis, 59:239  
 5-hydroxyindoleacetic acid, schizophrenia, 59:161, 59:239  
 5-hydroxyindoleacetic acid, statistics, 59:239  
 5-hydroxyindoleacetic acid, violence, 59:161  
 imipramine, pharmacokinetics, 59:189  
 impulsivity, paroxetine, 60:177  
 meta-analysis, 5-hydroxyindoleacetic acid, serotonin, schizophrenia, 59:239  
 meta-chlorophenylpiperazine, borderline personality, 58:161  
 meta-chlorophenylpiperazine, obsessive-compulsive disorder, 58:161  
 meta-chlorophenylpiperazine, panic disorder, 58:161  
 meta-chlorophenylpiperazine, personality disorder, 58:161  
 meta-chlorophenylpiperazine, pindolol, 58:89  
 meta-chlorophenylpiperazine, social phobia, 58:161  
 naltrexone, autism, 58:191  
 obsessive-compulsive disorder, meta-chlorophenylpiperazine, 58:161  
 obsessive-compulsive disorder, paroxetine binding, 58:117  
 ondansetron, affective disorder, computed tomography, 60:33  
 oppositional-defiant disorder, genetics, 57:13  
 panic disorder, meta-chlorophenylpiperazine, 58:161  
 panic disorder, personality disorder, 58:161  
 paroxetine, affective disorder, 58:117, 59:189  
 paroxetine binding, obsessive-compulsive disorder, 58:117  
 paroxetine binding, platelet, 58:117  
 paroxetine, impulsivity, 60:177  
 paroxetine, pharmacokinetics, 59:189  
 personality, bufotenin, 58:145  
 personality disorder, meta-chlorophenylpiperazine, 58:161  
 personality, impulsivity, paroxetine, 60:177  
 personality, violence, 58:145  
 pindolol, meta-chlorophenylpiperazine, 58:89  
 schizophrenia, 5-hydroxyindoleacetic acid, serotonin, meta-analysis, 59:161, 59:239  
 schizophrenia, statistics, 59:239  
 schizophrenia, violence, 59:161  
 social phobia, meta-chlorophenylpiperazine, 58:161  
 statistics, meta-analysis, 5-hydroxyindoleacetic acid, serotonin, schizophrenia, 59:239  
 violence, bufotenin, 58:145  
 violence, 5-hydroxyindoleacetic acid, 59:161  
 violence, personality, 58:145  
 violence, schizophrenia, 59:161
- Sex**  
 affective disorder, epidemiology, 58:1  
 anxiety disorder, epidemiology, 58:1  
 cognition, memory, schizoaffective disorder, schizophrenia, social skill, 57:141  
 epidemiology, affective disorder, anxiety disorder, 58:1  
 memory, schizoaffective disorder, schizophrenia, social skill, 57:141  
 schizoaffective disorder, cognition, memory, social skill, 57:141  
 schizophrenia, cognition, memory, social skill, 57:141  
 social skill, cognition, memory, schizoaffective disorder, schizophrenia, 57:141
- Skin conductance**  
 affective disorder, anhedonia, 56:163  
 affective disorder, bipolar subtype, 56:163  
 affective disorder, laterality, 56:163  
 anhedonia, bipolar affective disorder, laterality, 56:163  
 anhedonia, schizoaffective disorder, schizophrenia, 56:163  
 bipolar affective disorder, anhedonia, laterality, 56:163  
 disorganized symptoms, schizoaffective disorder, schizophrenia, 57:241  
 haloperidol, positive and negative symptoms, schizophrenia, 57:49  
 laterality, bipolar affective disorder, anhedonia, 56:163  
 laterality, schizoaffective disorder, schizophrenia, 56:163  
 negative symptoms, schizoaffective disorder, 57:241  
 negative symptoms, schizophrenia, 57:49, 57:241  
 positive symptoms, haloperidol, 57:49  
 positive symptoms, schizoaffective disorder, 57:241  
 positive symptoms, schizophrenia, 57:49, 57:241  
 schizoaffective disorder, anhedonia, 56:163  
 schizoaffective disorder, disorganized symptoms, 57:241  
 schizoaffective disorder, laterality, 56:163  
 schizoaffective disorder, positive and negative symptoms, 57:241  
 schizophrenia, anhedonia, 56:163  
 schizophrenia, disorganized symptoms, 57:241  
 schizophrenia, haloperidol, 57:49  
 schizophrenia, laterality, 56:163  
 schizophrenia, positive and negative symptoms, 57:49, 57:241
- Sleep. See Polysomnography; Sleep deprivation**
- Sleep deprivation**  
 affective disorder, Arden ratio, electrooculography, 57:197  
 circadian rhythm, visual adaptation, 57:197  
 electrooculography, circadian rhythm, visual adaptation, 57:197
- Social phobia**  
 neuropeptide Y, stress, 59:183  
 norepinephrine, stress, 59:183  
 peptides, stress, 59:183  
 stress, neuropeptide Y, 59:183  
 stress, norepinephrine, 59:183  
 stress, peptides, 59:183



**Social skill**

attention, cognition, neuropsychology, schizophrenia, sex effects, 59:213

**Statistics**

meta-analysis, 5-hydroxyindoleacetic acid, serotonin, schizophrenia, 59:239

**Stress. See Child abuse; Peptides; Posttraumatic stress disorder**  
**Structured Clinical Interview for BICDSM-III-RBIC**

anxiety, human immunodeficiency virus, intake interview, 59:245

depression, human immunodeficiency virus, intake interview, 59:245

human immunodeficiency virus, anxiety, depression, intake interview, 59:245

**Substance dependence**

age, genetics, race, sex, 56:213

alcohol, cocaine, marijuana, electroencephalography, 58:247

cocaine, alcohol, 58:247

cocaine, crack, cognition, 60:167

cocaine, marijuana, electroencephalography, 58:247

cocaine, crack, neuropsychology, 60:167

cognition, cocaine, crack, 60:167

comorbid depression, heroin, 58:153

electroencephalography, alcohol, cocaine, marijuana, 58:247

epidemiology, genetics, 57:169

Family History Screen for Epidemiologic Studies, genetics, 57:169

fenfluramine, heroin, 58:153

genetics, Family History Screen for Epidemiologic Studies, 57:169

genetics, race, sex, 56:213

genetics, twin study, 56:213

heroin abuse, comorbid depression, 58:153

marijuana, alcohol, cocaine, electroencephalography, 58:247

neuropsychology, cocaine, crack, 60:167

prolactin, heroin abuse, 58:153

race, age, sex, genetics, 56:213

sex, age, race, genetics, 56:213

twin study, age, sex, race, 56:213

**Tardive dyskinesia**

Abnormal Involuntary Movements Scale, circadian rhythm, 56:53

Abnormal Involuntary Movements Scale, haloperidol, 56:53

Abnormal Involuntary Movements Scale, schizophrenia, 56:53

circadian rhythm, Abnormal Involuntary Movements Scale, 56:53

haloperidol, Abnormal Involuntary Movements Scale,

schizophrenia, 56:53

schizophrenia, circadian rhythm, 56:53

**Thyroid hormones**

affective disorder, thyroid-stimulating hormone, 57:41

affective disorder, thyrotropin-releasing hormone, 57:41

circadian rhythm, schizophrenia, 57:21

schizophrenia, circadian rhythm, 57:21

thyroid-stimulating hormone, affective disorder, 57:41

thyrotropin-releasing hormone, affective disorder, 57:41

**Tridimensional Personality Questionnaire**

affective disorder, bipolar subtype, 57:209, 58:139

affective disorder, harm avoidance, 57:209, 58:139

affective disorder, novelty seeking, 58:139

affective disorder, unipolar subtype, 58:139

bipolar affective disorder, harm avoidance, 57:209, 58:139

bipolar affective disorder, novelty seeking, 58:139

harm avoidance, affective disorder, bipolar subtype, 57:209, 58:139

harm avoidance, unipolar subtype, 58:139

novelty seeking, affective disorder, bipolar subtype, 58:139

novelty seeking, unipolar subtype, 58:139

**Vanillylmandelic acid**

anxiety disorder, norepinephrine, 57:1

norepinephrine, anxiety disorder, 57:1

**Ventricle-brain ratio. See Computed tomography****Violence**

affective disorder, circadian and circannual rhythm, photoperiod, 60:199

bufotenin, personality type, serotonin, 58:145

circadian rhythm, affective disorder, schizophrenia, 60:199

circannual rhythm, affective disorder, schizophrenia, 60:199

5-hydroxyindoleacetic acid, schizophrenia, 59:161

schizophrenia, circadian and circannual rhythm, 60:199

schizophrenia, 5-hydroxyindoleacetic acid, serotonin, 59:161

serotonin, bufotenin, 58:145

serotonin, schizophrenia, 59:161